WO2006016689A1 - Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 - Google Patents
Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 Download PDFInfo
- Publication number
- WO2006016689A1 WO2006016689A1 PCT/JP2005/014875 JP2005014875W WO2006016689A1 WO 2006016689 A1 WO2006016689 A1 WO 2006016689A1 JP 2005014875 W JP2005014875 W JP 2005014875W WO 2006016689 A1 WO2006016689 A1 WO 2006016689A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- substituted
- ring
- hydroxy
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title claims abstract description 74
- 208000012931 Urologic disease Diseases 0.000 title claims abstract description 40
- 208000014001 urinary system disease Diseases 0.000 title claims abstract description 40
- 230000003449 preventive effect Effects 0.000 title claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 34
- 201000003146 cystitis Diseases 0.000 claims abstract description 34
- 230000027939 micturition Effects 0.000 claims abstract description 29
- 208000024891 symptom Diseases 0.000 claims abstract description 25
- 210000004877 mucosa Anatomy 0.000 claims abstract description 16
- 208000002193 Pain Diseases 0.000 claims abstract description 13
- 230000036407 pain Effects 0.000 claims abstract description 13
- 210000001635 urinary tract Anatomy 0.000 claims abstract description 13
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 12
- 230000008929 regeneration Effects 0.000 claims abstract description 11
- 238000011069 regeneration method Methods 0.000 claims abstract description 11
- 208000005615 Interstitial Cystitis Diseases 0.000 claims abstract description 9
- 206010062225 Urinary tract pain Diseases 0.000 claims abstract description 9
- 206010005063 Bladder pain Diseases 0.000 claims abstract description 7
- 208000000450 Pelvic Pain Diseases 0.000 claims abstract description 7
- 206010061339 Perineal pain Diseases 0.000 claims abstract description 7
- 206010039757 Scrotal pain Diseases 0.000 claims abstract description 7
- 206010069055 Vulvovaginal pain Diseases 0.000 claims abstract description 7
- 230000001737 promoting effect Effects 0.000 claims abstract description 6
- 208000000143 urethritis Diseases 0.000 claims abstract description 6
- 206010061218 Inflammation Diseases 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 387
- -1 chael group Chemical group 0.000 claims description 161
- 150000001875 compounds Chemical class 0.000 claims description 135
- 125000001424 substituent group Chemical group 0.000 claims description 135
- 125000003545 alkoxy group Chemical group 0.000 claims description 124
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 107
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 87
- 125000005843 halogen group Chemical group 0.000 claims description 75
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 70
- 239000003814 drug Substances 0.000 claims description 70
- 229910052757 nitrogen Inorganic materials 0.000 claims description 61
- 125000002947 alkylene group Chemical group 0.000 claims description 59
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 54
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 53
- 125000004414 alkyl thio group Chemical group 0.000 claims description 48
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 43
- 229910052717 sulfur Inorganic materials 0.000 claims description 42
- 125000000623 heterocyclic group Chemical group 0.000 claims description 40
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 39
- 229940002612 prodrug Drugs 0.000 claims description 37
- 239000000651 prodrug Substances 0.000 claims description 37
- 239000012453 solvate Substances 0.000 claims description 35
- 229920000858 Cyclodextrin Polymers 0.000 claims description 34
- 125000004429 atom Chemical group 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 33
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 33
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 33
- 125000004434 sulfur atom Chemical group 0.000 claims description 33
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 31
- 150000001204 N-oxides Chemical class 0.000 claims description 31
- 125000004122 cyclic group Chemical group 0.000 claims description 31
- 229940124597 therapeutic agent Drugs 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 30
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 28
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 27
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 125000002252 acyl group Chemical group 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 20
- 125000002950 monocyclic group Chemical group 0.000 claims description 20
- 125000000304 alkynyl group Chemical group 0.000 claims description 19
- 229920006395 saturated elastomer Polymers 0.000 claims description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 125000004450 alkenylene group Chemical group 0.000 claims description 17
- 239000011593 sulfur Substances 0.000 claims description 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000002619 bicyclic group Chemical group 0.000 claims description 14
- 208000026723 Urinary tract disease Diseases 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 239000000446 fuel Substances 0.000 claims description 12
- 125000002541 furyl group Chemical group 0.000 claims description 12
- 210000004392 genitalia Anatomy 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 230000002378 acidificating effect Effects 0.000 claims description 10
- 125000004423 acyloxy group Chemical group 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 125000006267 biphenyl group Chemical group 0.000 claims description 9
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 229910052708 sodium Inorganic materials 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 206010046461 Urethral pain Diseases 0.000 claims description 6
- 239000000043 antiallergic agent Substances 0.000 claims description 6
- 239000000935 antidepressant agent Substances 0.000 claims description 6
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 claims description 6
- 125000006850 spacer group Chemical group 0.000 claims description 6
- 206010005052 Bladder irritation Diseases 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 5
- 239000001961 anticonvulsive agent Substances 0.000 claims description 5
- 229940005513 antidepressants Drugs 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 150000003536 tetrazoles Chemical class 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 125000005366 cycloalkylthio group Chemical group 0.000 claims description 4
- KPSZWAJWFMFMFF-UHFFFAOYSA-N hept-5-enoic acid Chemical compound CC=CCCCC(O)=O KPSZWAJWFMFMFF-UHFFFAOYSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 206010063057 Cystitis noninfective Diseases 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 229940125681 anticonvulsant agent Drugs 0.000 claims description 3
- 229940125715 antihistaminic agent Drugs 0.000 claims description 3
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 208000006750 hematuria Diseases 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- UPUWMQZUXFAUCJ-UHFFFAOYSA-N 2,5-dihydro-1,2-thiazole Chemical compound C1SNC=C1 UPUWMQZUXFAUCJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
- 206010005042 Bladder fibrosis Diseases 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 claims 1
- CTWNEGPLIQQJDO-UHFFFAOYSA-N 1,3,2-dioxathiocane 2,2-dioxide Chemical compound O=S1(=O)OCCCCCO1 CTWNEGPLIQQJDO-UHFFFAOYSA-N 0.000 claims 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims 1
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 claims 1
- LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 claims 1
- JKTORXLUQLQJCM-UHFFFAOYSA-N 4-phosphonobutylphosphonic acid Chemical compound OP(O)(=O)CCCCP(O)(O)=O JKTORXLUQLQJCM-UHFFFAOYSA-N 0.000 claims 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 210000005000 reproductive tract Anatomy 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract 2
- 230000001850 reproductive effect Effects 0.000 abstract 2
- 208000024470 urgency of urination Diseases 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 description 64
- 125000003118 aryl group Chemical group 0.000 description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 230000009471 action Effects 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 18
- 229960004397 cyclophosphamide Drugs 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 239000002253 acid Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
- 239000013543 active substance Substances 0.000 description 14
- 125000003277 amino group Chemical group 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 239000003755 preservative agent Substances 0.000 description 13
- 125000000547 substituted alkyl group Chemical group 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 10
- 125000004404 heteroalkyl group Chemical group 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 125000004043 oxo group Chemical group O=* 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 239000003963 antioxidant agent Substances 0.000 description 9
- 125000002837 carbocyclic group Chemical group 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000013355 food flavoring agent Nutrition 0.000 description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 9
- 125000003367 polycyclic group Chemical group 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 230000002485 urinary effect Effects 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 239000004220 glutamic acid Substances 0.000 description 8
- 235000013922 glutamic acid Nutrition 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 229940083542 sodium Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 6
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 235000014121 butter Nutrition 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 5
- 208000010201 Exanthema Diseases 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 5
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 125000004419 alkynylene group Chemical group 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000000000 cycloalkoxy group Chemical group 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 5
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 125000003003 spiro group Chemical group 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 4
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 4
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000004953 trihalomethyl group Chemical group 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 3
- XLFJAKYQFYKWKQ-UHFFFAOYSA-N 3-(ethoxymethyl)phenol Chemical compound CCOCC1=CC=CC(O)=C1 XLFJAKYQFYKWKQ-UHFFFAOYSA-N 0.000 description 3
- WHGMHGPIJZTKTI-UHFFFAOYSA-N 3h-1,2-benzodithiole Chemical compound C1=CC=C2CSSC2=C1 WHGMHGPIJZTKTI-UHFFFAOYSA-N 0.000 description 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 3
- 235000006679 Mentha X verticillata Nutrition 0.000 description 3
- 235000002899 Mentha suaveolens Nutrition 0.000 description 3
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 206010046555 Urinary retention Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 3
- 125000005108 alkenylthio group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 description 3
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000036724 intravesical pressure Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- FWLKKPKZQYVAFR-LVEZLNDCSA-N (e)-but-2-enedioic acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-LVEZLNDCSA-N 0.000 description 2
- RXBYRTSOWREATF-UHFFFAOYSA-N 1,2,3,4-tetrahydroacridine Chemical compound C1=CC=C2C=C(CCCC3)C3=NC2=C1 RXBYRTSOWREATF-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- FHGWEHGZBUBQKL-UHFFFAOYSA-N 1,2-benzothiazepine Chemical compound S1N=CC=CC2=CC=CC=C12 FHGWEHGZBUBQKL-UHFFFAOYSA-N 0.000 description 2
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 2
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 description 2
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
- LYTMVABTDYMBQK-UHFFFAOYSA-N 2-benzothiophene Chemical compound C1=CC=CC2=CSC=C21 LYTMVABTDYMBQK-UHFFFAOYSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010061979 Genital pain Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- RXZMMZZRUPYENV-VROPFNGYSA-N Solifenacin succinate Chemical compound OC(=O)CCC(O)=O.C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 RXZMMZZRUPYENV-VROPFNGYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 241000009298 Trigla lyra Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 244000290333 Vanilla fragrans Species 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 2
- 239000003655 absorption accelerator Substances 0.000 description 2
- 229940124532 absorption promoter Drugs 0.000 description 2
- MGVGMXLGOKTYKP-ZFOBEOMCSA-N acetic acid;(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one Chemical compound CC(O)=O.C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 MGVGMXLGOKTYKP-ZFOBEOMCSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- 235000011037 adipic acid Nutrition 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000005133 alkynyloxy group Chemical group 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 125000005577 anthracene group Chemical group 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- TYNZVWXDLOJTIM-QQFWICJTSA-N astromycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O[C@@H]1[C@H](N(C)C(=O)CN)[C@@H](OC)[C@@H](O)[C@H](N)[C@H]1O[C@@H]1[C@H](N)CC[C@@H]([C@H](C)N)O1 TYNZVWXDLOJTIM-QQFWICJTSA-N 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 2
- 229960004335 azelastine hydrochloride Drugs 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 2
- 229960002071 bepotastine Drugs 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940053031 botulinum toxin Drugs 0.000 description 2
- CHRHZFQUDFAQEQ-UHFFFAOYSA-L calcium;2-hydroxyacetate Chemical compound [Ca+2].OCC([O-])=O.OCC([O-])=O CHRHZFQUDFAQEQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 229960003657 dexamethasone acetate Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 2
- 229960001971 ebastine Drugs 0.000 description 2
- 229960000325 emedastine Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 2
- 229960002548 epinastine hydrochloride Drugs 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- OTTZHAVKAVGASB-UHFFFAOYSA-N hept-2-ene Chemical compound CCCCC=CC OTTZHAVKAVGASB-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- SQKXYSGRELMAAU-UHFFFAOYSA-N imidafenacin Chemical compound CC1=NC=CN1CCC(C(N)=O)(C=1C=CC=CC=1)C1=CC=CC=C1 SQKXYSGRELMAAU-UHFFFAOYSA-N 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- GUCYBPFJNGVFEB-XELKFLSISA-N iseganan Chemical compound C([C@H]1C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(N1)=O)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C(C)C)C1=CC=C(O)C=C1 GUCYBPFJNGVFEB-XELKFLSISA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229960001293 methylprednisolone acetate Drugs 0.000 description 2
- 229960001664 mometasone Drugs 0.000 description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 2
- DTHHUAXKOMWYBI-UHFFFAOYSA-N oxadiazolidine Chemical compound C1CONN1 DTHHUAXKOMWYBI-UHFFFAOYSA-N 0.000 description 2
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 2
- 229960002698 oxatomide Drugs 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- 125000004585 polycyclic heterocycle group Chemical group 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 238000011470 radical surgery Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940101201 ringl Drugs 0.000 description 2
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 229940074404 sodium succinate Drugs 0.000 description 2
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 125000005750 substituted cyclic group Chemical group 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- RLTPJVKHGBFGQA-UHFFFAOYSA-N thiadiazolidine Chemical compound C1CSNN1 RLTPJVKHGBFGQA-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 2
- 229960005342 tranilast Drugs 0.000 description 2
- 229940126307 triamcinolone acetate Drugs 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- BNJMRELGMDUDDB-UHFFFAOYSA-N $l^{1}-sulfanylbenzene Chemical compound [S]C1=CC=CC=C1 BNJMRELGMDUDDB-UHFFFAOYSA-N 0.000 description 1
- CIDUJQMULVCIBT-CWCLBWQUSA-N (2R,3R,4R,5R)-2-[(1S,2S,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound CCN[C@@H]1C[C@H](N)[C@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O CIDUJQMULVCIBT-CWCLBWQUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MYZDPUZXMFCPMU-LRIWMWCYSA-N (6r,8s,9r,10s,11s,13s,14s,17r)-2-bromo-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound O=C1C(Br)=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@@H](F)C2=C1 MYZDPUZXMFCPMU-LRIWMWCYSA-N 0.000 description 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- SYTBZMRGLBWNTM-SNVBAGLBSA-N (R)-flurbiprofen Chemical compound FC1=CC([C@H](C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-SNVBAGLBSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- VKJHANNFFHMLBB-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydrocinnoline Chemical compound N1NCCC2CCCCC21 VKJHANNFFHMLBB-UHFFFAOYSA-N 0.000 description 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 description 1
- HZNXIPDYYIWDNM-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinazoline Chemical compound N1CNCC2CCCCC21 HZNXIPDYYIWDNM-UHFFFAOYSA-N 0.000 description 1
- XTDNMGZRUWMVLT-UHFFFAOYSA-N 1,2,3,4,4a,5a,6,7,8,9,9a,9b-dodecahydrodibenzofuran Chemical compound C1CCCC2C3CCCCC3OC21 XTDNMGZRUWMVLT-UHFFFAOYSA-N 0.000 description 1
- XMJFSCXZDZSDJS-UHFFFAOYSA-N 1,2,3,4,4a,5a,6,7,8,9,9a,9b-dodecahydrodibenzothiophene Chemical compound C1CCCC2C3CCCCC3SC21 XMJFSCXZDZSDJS-UHFFFAOYSA-N 0.000 description 1
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 1
- WXRSSOIHEAVYLL-UHFFFAOYSA-N 1,2,3,4-tetrahydrocinnoline Chemical compound C1=CC=C2NNCCC2=C1 WXRSSOIHEAVYLL-UHFFFAOYSA-N 0.000 description 1
- JCLPOPNXITXHOR-UHFFFAOYSA-N 1,2,3,4-tetrahydrodibenzothiophene Chemical compound S1C2=CC=CC=C2C2=C1CCCC2 JCLPOPNXITXHOR-UHFFFAOYSA-N 0.000 description 1
- STIWEDICJHIFJT-UHFFFAOYSA-N 1,2,3,4-tetrahydrophthalazine Chemical compound C1=CC=C2CNNCC2=C1 STIWEDICJHIFJT-UHFFFAOYSA-N 0.000 description 1
- OQJVXNHMUWQQEW-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrazine Chemical compound C1CNC=CN1 OQJVXNHMUWQQEW-UHFFFAOYSA-N 0.000 description 1
- JQIZHNLEFQMDCQ-UHFFFAOYSA-N 1,2,3,4-tetrahydropyridazine Chemical compound C1CC=CNN1 JQIZHNLEFQMDCQ-UHFFFAOYSA-N 0.000 description 1
- PKORYTIUMAOPED-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinazoline Chemical compound C1=CC=C2NCNCC2=C1 PKORYTIUMAOPED-UHFFFAOYSA-N 0.000 description 1
- HORKYAIEVBUXGM-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoxaline Chemical compound C1=CC=C2NCCNC2=C1 HORKYAIEVBUXGM-UHFFFAOYSA-N 0.000 description 1
- UUZJJNBYJDFQHL-UHFFFAOYSA-N 1,2,3-triazolidine Chemical compound C1CNNN1 UUZJJNBYJDFQHL-UHFFFAOYSA-N 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- XEYKWYIXHMEQGM-UHFFFAOYSA-N 1,2-dihydro-1,8-naphthyridine Chemical compound C1=CC=C2C=CCNC2=N1 XEYKWYIXHMEQGM-UHFFFAOYSA-N 0.000 description 1
- UXJHQQLYKUVLIE-UHFFFAOYSA-N 1,2-dihydroacridine Chemical compound C1=CC=C2N=C(C=CCC3)C3=CC2=C1 UXJHQQLYKUVLIE-UHFFFAOYSA-N 0.000 description 1
- QRDNXAYNXUKMOO-UHFFFAOYSA-N 1,2-dihydrocinnoline Chemical compound C1=CC=C2C=CNNC2=C1 QRDNXAYNXUKMOO-UHFFFAOYSA-N 0.000 description 1
- AYMOVGCUZMUZSI-UHFFFAOYSA-N 1,2-dihydrodibenzothiophene Chemical compound S1C2=CC=CC=C2C2=C1C=CCC2 AYMOVGCUZMUZSI-UHFFFAOYSA-N 0.000 description 1
- IOEPOEDBBPRAEI-UHFFFAOYSA-N 1,2-dihydroisoquinoline Chemical compound C1=CC=C2CNC=CC2=C1 IOEPOEDBBPRAEI-UHFFFAOYSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- QYMGRIFMUQCAJW-UHFFFAOYSA-N 1,2-dihydropyrazine Chemical compound C1NC=CN=C1 QYMGRIFMUQCAJW-UHFFFAOYSA-N 0.000 description 1
- BKWQKVJYXODDAC-UHFFFAOYSA-N 1,2-dihydropyridazine Chemical compound N1NC=CC=C1 BKWQKVJYXODDAC-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- XXBQLHATYQHJQC-UHFFFAOYSA-N 1,2-dihydroquinoxaline Chemical compound C1=CC=C2N=CCNC2=C1 XXBQLHATYQHJQC-UHFFFAOYSA-N 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N 1-Heptene Chemical group CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- JVCBVWTTXCNJBJ-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptane Chemical compound C1CC2CCN1C2 JVCBVWTTXCNJBJ-UHFFFAOYSA-N 0.000 description 1
- STHHLVCQSLRQNI-UHFFFAOYSA-N 1-azabicyclo[3.2.1]octane Chemical compound C1C2CCN1CCC2 STHHLVCQSLRQNI-UHFFFAOYSA-N 0.000 description 1
- FJGFHPNQSDXCFC-UHFFFAOYSA-N 1-azaspiro[4.4]nonane Chemical compound C1CCCC21NCCC2 FJGFHPNQSDXCFC-UHFFFAOYSA-N 0.000 description 1
- XYUPPXPJWYLXSW-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=C[CH]C2=C=COC2=C1 XYUPPXPJWYLXSW-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- UDMSIVPAVKUOKF-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1,2-benzoxazepine Chemical compound C1CCNOC2=CC=CC=C21 UDMSIVPAVKUOKF-UHFFFAOYSA-N 0.000 description 1
- QEYQSYAGLRIYBE-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1,2-benzodiazepine Chemical compound C1CCNNC2=CC=CC=C21 QEYQSYAGLRIYBE-UHFFFAOYSA-N 0.000 description 1
- SCEIUGQQBYRBPP-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-azepine Chemical compound C1CCC=CNC1 SCEIUGQQBYRBPP-UHFFFAOYSA-N 0.000 description 1
- YYVKQFQZKSLYFN-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-diazepine Chemical compound C1CNNC=CC1 YYVKQFQZKSLYFN-UHFFFAOYSA-N 0.000 description 1
- GLCYMVDVOVIDBB-UHFFFAOYSA-N 2,3,4,5-tetrahydrooxadiazepine Chemical compound C1CC=CONN1 GLCYMVDVOVIDBB-UHFFFAOYSA-N 0.000 description 1
- WHUAPUGLAGYTQS-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiadiazepine Chemical compound C1CC=CSNN1 WHUAPUGLAGYTQS-UHFFFAOYSA-N 0.000 description 1
- IFPKIMVCYSSDDJ-UHFFFAOYSA-N 2,3,4,5-tetrahydrothiazepine Chemical compound C1CNSC=CC1 IFPKIMVCYSSDDJ-UHFFFAOYSA-N 0.000 description 1
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- RIUSCLBEBIOIRP-UHFFFAOYSA-N 2,3-dihydro-1,2-benzoxazepine Chemical compound C1=CCNOC2=CC=CC=C21 RIUSCLBEBIOIRP-UHFFFAOYSA-N 0.000 description 1
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 description 1
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- YJUFGFXVASPYFQ-UHFFFAOYSA-N 2,3-dihydro-1-benzothiophene Chemical compound C1=CC=C2SCCC2=C1 YJUFGFXVASPYFQ-UHFFFAOYSA-N 0.000 description 1
- ZWWWYOKRVNYQHF-UHFFFAOYSA-N 2,3-dihydro-1h-1,2-benzodiazepine Chemical compound C1=CCNNC2=CC=CC=C21 ZWWWYOKRVNYQHF-UHFFFAOYSA-N 0.000 description 1
- BEWVAZNECYSPMT-UHFFFAOYSA-N 2,3-dihydro-1h-azepine Chemical compound C1CC=CC=CN1 BEWVAZNECYSPMT-UHFFFAOYSA-N 0.000 description 1
- QHYXWSXPPUTDRA-UHFFFAOYSA-N 2,3-dihydro-1h-diazepine Chemical compound C1NNC=CC=C1 QHYXWSXPPUTDRA-UHFFFAOYSA-N 0.000 description 1
- IZEOXCXHDBQQAP-UHFFFAOYSA-N 2,3-dihydrothiazepine Chemical compound C1NSC=CC=C1 IZEOXCXHDBQQAP-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- PZJFUNZDCRKXPZ-UHFFFAOYSA-N 2,5-dihydro-1h-tetrazole Chemical compound C1NNN=N1 PZJFUNZDCRKXPZ-UHFFFAOYSA-N 0.000 description 1
- ZECQLHQEHJJSAN-UHFFFAOYSA-N 2,9-dihydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCC=C2 ZECQLHQEHJJSAN-UHFFFAOYSA-N 0.000 description 1
- ZZIZZTHXZRDOFM-UHFFFAOYSA-N 2-(2-ethoxyphenoxy)ethyl-[1-(4-methoxy-3-sulfamoylphenyl)propan-2-yl]azanium;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- WGTASENVNYJZBK-UHFFFAOYSA-N 3,4,5-trimethoxyamphetamine Chemical compound COC1=CC(CC(C)N)=CC(OC)=C1OC WGTASENVNYJZBK-UHFFFAOYSA-N 0.000 description 1
- IDUSJBBWEKNWAK-UHFFFAOYSA-N 3,4-dihydro-2h-1,2-benzothiazine Chemical compound C1=CC=C2SNCCC2=C1 IDUSJBBWEKNWAK-UHFFFAOYSA-N 0.000 description 1
- BOLMDIXLULGTBD-UHFFFAOYSA-N 3,4-dihydro-2h-oxazine Chemical compound C1CC=CON1 BOLMDIXLULGTBD-UHFFFAOYSA-N 0.000 description 1
- NWWJFMCCTZLKNT-UHFFFAOYSA-N 3,4-dihydro-2h-thiazine Chemical compound C1CC=CSN1 NWWJFMCCTZLKNT-UHFFFAOYSA-N 0.000 description 1
- ATVJJNGVPSKBGO-UHFFFAOYSA-N 3,4-dihydro-2h-thiopyran Chemical compound C1CSC=CC1 ATVJJNGVPSKBGO-UHFFFAOYSA-N 0.000 description 1
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 1
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical group C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 description 1
- GPYDBWWOYRNOBL-UHFFFAOYSA-N 4,5-dihydro-3h-1,2-benzodioxepine Chemical compound C1CCOOC2=CC=CC=C21 GPYDBWWOYRNOBL-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- HXXOPVULXOEHTK-UHFFFAOYSA-N 4-methyl-1,3-dioxol-2-one Chemical compound CC1=COC(=O)O1 HXXOPVULXOEHTK-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 description 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 description 1
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- TWHZNAUBXFZMCA-UHFFFAOYSA-N Acotiamide Chemical compound C1=C(OC)C(OC)=CC(O)=C1C(=O)NC1=NC(C(=O)NCCN(C(C)C)C(C)C)=CS1 TWHZNAUBXFZMCA-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010049576 Bladder neck sclerosis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- YWFJNRNQLAYWDP-UHFFFAOYSA-N C1COC2=C3C=CC=CC3=C4C=CC=CC4C21 Chemical compound C1COC2=C3C=CC=CC3=C4C=CC=CC4C21 YWFJNRNQLAYWDP-UHFFFAOYSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 1
- 241000179924 Chelus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010814 Contracted bladder Diseases 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010056246 Eosinophilic cystitis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IKYCZSUNGFRBJS-UHFFFAOYSA-N Euphorbia factor RL9 = U(1) = Resiniferatoxin Natural products COC1=CC(O)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 IKYCZSUNGFRBJS-UHFFFAOYSA-N 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 239000001293 FEMA 3089 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- DHUZAAUGHUHIDS-ONEGZZNKSA-N Isomyristicin Chemical compound COC1=CC(\C=C\C)=CC2=C1OCO2 DHUZAAUGHUHIDS-ONEGZZNKSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 101150079116 MT-CO1 gene Proteins 0.000 description 1
- 208000010495 Meningocele Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 241001082018 Mometa Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- HYRKAAMZBDSJFJ-LFDBJOOHSA-N Paramethasone acetate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]2(C)C[C@@H]1O HYRKAAMZBDSJFJ-LFDBJOOHSA-N 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- HUMXXHTVHHLNRO-KAJVQRHHSA-N Prednisolone tebutate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC(C)(C)C)(O)[C@@]1(C)C[C@@H]2O HUMXXHTVHHLNRO-KAJVQRHHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000008718 Pyuria Diseases 0.000 description 1
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010069645 Reduced bladder capacity Diseases 0.000 description 1
- 206010038731 Respiratory tract irritation Diseases 0.000 description 1
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 229920013631 Sulfar Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- XQTARQNQIVVBRX-UHFFFAOYSA-N Tazanolast Chemical compound CCCCOC(=O)C(=O)NC1=CC=CC(C2=NNN=N2)=C1 XQTARQNQIVVBRX-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 description 1
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- UKNGDQSYPNBJAO-UHFFFAOYSA-N Tiaramide hydrochloride Chemical compound Cl.C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 UKNGDQSYPNBJAO-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 206010065584 Urethral stenosis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 1
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 1
- FBRAWBYQGRLCEK-UHFFFAOYSA-N [17-(2-chloroacetyl)-9-fluoro-10,13,16-trimethyl-3,11-dioxo-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)C=CC2(C)C2(F)C1C1CC(C)C(C(=O)CCl)(OC(=O)CCC)C1(C)CC2=O FBRAWBYQGRLCEK-UHFFFAOYSA-N 0.000 description 1
- RYVJQEZJUFRANT-UHFFFAOYSA-N [3-[4-(3-ethoxy-2-hydroxypropoxy)anilino]-3-oxopropyl]-dimethylsulfanium;4-methylbenzenesulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CCOCC(O)COC1=CC=C(NC(=O)CC[S+](C)C)C=C1 RYVJQEZJUFRANT-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- HZWXJJCSDBQVLF-UHFFFAOYSA-N acetoxysulfonic acid Chemical compound CC(=O)OS(O)(=O)=O HZWXJJCSDBQVLF-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229950005462 acotiamide Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000005661 acute cystitis Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000005109 alkynylthio group Chemical group 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 1
- 229960003731 amlexanox Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 150000005405 azaspiro[5.5]undecanes Chemical group 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
- FTMRMQALUDDFQO-UHFFFAOYSA-N beta-brazan Natural products C1=CC=C2C=C3C4=CC=CC=C4OC3=CC2=C1 FTMRMQALUDDFQO-UHFFFAOYSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- VXOWJCTXWVWLLC-REGDIAEZSA-N betamethasone butyrate propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O VXOWJCTXWVWLLC-REGDIAEZSA-N 0.000 description 1
- 229950008408 betamethasone butyrate propionate Drugs 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 201000000563 bladder tuberculosis Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960000534 cefuroxime sodium Drugs 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 201000003139 chronic cystitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960005465 clobetasone butyrate Drugs 0.000 description 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- MAEBCGDGGATMSC-OSHGGGOQSA-N cyclamine Chemical compound O([C@H]1CO[C@H]([C@@H]([C@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CCC45OCC6([C@@H](C[C@@]4(C)[C@]3(C)CCC2C1(C)C)O)CC[C@@](C[C@@H]65)(C)C=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O MAEBCGDGGATMSC-OSHGGGOQSA-N 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 1
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical compound C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 description 1
- GPTJTTCOVDDHER-UHFFFAOYSA-N cyclononane Chemical compound C1CCCCCCCC1 GPTJTTCOVDDHER-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- SRONXYPFSAKOGH-UHFFFAOYSA-N cyclopentadecane Chemical compound C1CCCCCCCCCCCCCC1 SRONXYPFSAKOGH-UHFFFAOYSA-N 0.000 description 1
- KATXJJSCAPBIOB-UHFFFAOYSA-N cyclotetradecane Chemical compound C1CCCCCCCCCCCCC1 KATXJJSCAPBIOB-UHFFFAOYSA-N 0.000 description 1
- UEVXKGPJXXDGCX-UHFFFAOYSA-N cyclotridecane Chemical compound C1CCCCCCCCCCCC1 UEVXKGPJXXDGCX-UHFFFAOYSA-N 0.000 description 1
- KYTNZWVKKKJXFS-UHFFFAOYSA-N cycloundecane Chemical compound C1CCCCCCCCCC1 KYTNZWVKKKJXFS-UHFFFAOYSA-N 0.000 description 1
- 238000009799 cystectomy Methods 0.000 description 1
- 229960002677 darifenacin Drugs 0.000 description 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
- MSJQCBORNZDNDU-UHFFFAOYSA-D decasodium 3-methoxy-6-[2-(6-methoxy-4,5-disulfonatooxyoxan-3-yl)oxy-5-[5-(5-methoxy-3,4-disulfonatooxyoxan-2-yl)oxy-3,4-disulfonatooxyoxan-2-yl]oxy-4-sulfonatooxyoxan-3-yl]oxy-4,5-disulfonatooxyoxane-2-carboxylate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].COC1COC(OC2COC(OC3COC(OC4COC(OC)C(OS([O-])(=O)=O)C4OS([O-])(=O)=O)C(OC4OC(C(OC)C(OS([O-])(=O)=O)C4OS([O-])(=O)=O)C([O-])=O)C3OS([O-])(=O)=O)C(OS([O-])(=O)=O)C2OS([O-])(=O)=O)C(OS([O-])(=O)=O)C1OS([O-])(=O)=O MSJQCBORNZDNDU-UHFFFAOYSA-D 0.000 description 1
- ICODSBYUBBICCC-UHFFFAOYSA-D decasodium pentasulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ICODSBYUBBICCC-UHFFFAOYSA-D 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- XAEWZDYWZHIUCT-UHFFFAOYSA-N desipramine hydrochloride Chemical compound [H+].[Cl-].C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 XAEWZDYWZHIUCT-UHFFFAOYSA-N 0.000 description 1
- 229960003829 desipramine hydrochloride Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-PKWREOPISA-N dexamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-PKWREOPISA-N 0.000 description 1
- 229950000250 dexamethasone dipropionate Drugs 0.000 description 1
- 229950000812 dexamethasone palmitate Drugs 0.000 description 1
- 229960004833 dexamethasone phosphate Drugs 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 229950006825 dexamethasone valerate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- QPMLSUSACCOBDK-UHFFFAOYSA-N diazepane Chemical compound C1CCNNCC1 QPMLSUSACCOBDK-UHFFFAOYSA-N 0.000 description 1
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 229960004875 difluprednate Drugs 0.000 description 1
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
- 229960000807 dihydroergotamine mesylate Drugs 0.000 description 1
- ILYCWAKSDCYMBB-OPCMSESCSA-N dihydrotachysterol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1/C[C@@H](O)CC[C@@H]1C ILYCWAKSDCYMBB-OPCMSESCSA-N 0.000 description 1
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- JGKVKXPDDVRUKC-UHFFFAOYSA-N dimethothiazine mesylate Chemical compound CS(O)(=O)=O.C1=C(S(=O)(=O)N(C)C)C=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 JGKVKXPDDVRUKC-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960000220 doxazosin mesylate Drugs 0.000 description 1
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229940043249 elmiron Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- 229960001903 ergotamine tartrate Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 1
- 229960002767 ethosuximide Drugs 0.000 description 1
- 229960003533 ethotoin Drugs 0.000 description 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229940042902 flumethasone pivalate Drugs 0.000 description 1
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- DDTGNKBZWQHIEH-UHFFFAOYSA-N heptalene Chemical compound C1=CC=CC=C2C=CC=CC=C21 DDTGNKBZWQHIEH-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960002491 ibudilast Drugs 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960002056 indoramin Drugs 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960005042 mequitazine Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000036453 micturition reflex Effects 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- MGCQZNBCJBRZDT-UHFFFAOYSA-N midodrine hydrochloride Chemical compound [H+].[Cl-].COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 MGCQZNBCJBRZDT-UHFFFAOYSA-N 0.000 description 1
- 229960002728 midodrine hydrochloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HWMFFWCDLWDYGX-UHFFFAOYSA-N n-(4-aminophenyl)furan-2-carboxamide Chemical compound C1=CC(N)=CC=C1NC(=O)C1=CC=CO1 HWMFFWCDLWDYGX-UHFFFAOYSA-N 0.000 description 1
- MSXTUBJFNBZPGC-UHFFFAOYSA-N n-[4-oxo-2-(2h-tetrazol-5-yl)chromen-8-yl]-4-(4-phenylbutoxy)benzamide;hydrate Chemical compound O.C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1.C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1 MSXTUBJFNBZPGC-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- OTLYTKRAADUASA-UHFFFAOYSA-N oxadiazepane Chemical compound C1CCONNC1 OTLYTKRAADUASA-UHFFFAOYSA-N 0.000 description 1
- XCRJTRCPEJKXLR-UHFFFAOYSA-N oxadiazinane Chemical compound C1CNNOC1 XCRJTRCPEJKXLR-UHFFFAOYSA-N 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 description 1
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 description 1
- UHHKSVZZTYJVEG-UHFFFAOYSA-N oxepane Chemical compound C1CCCOCC1 UHHKSVZZTYJVEG-UHFFFAOYSA-N 0.000 description 1
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 1
- HZBAVWLZSLOCFR-UHFFFAOYSA-N oxosilane Chemical compound [SiH2]=O HZBAVWLZSLOCFR-UHFFFAOYSA-N 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 229960000865 paramethasone acetate Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960004811 pemirolast potassium Drugs 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- NMMVKSMGBDRONO-UHFFFAOYSA-N potassium;9-methyl-3-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound [K+].CC1=CC=CN(C2=O)C1=NC=C2C1=NN=N[N-]1 NMMVKSMGBDRONO-UHFFFAOYSA-N 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- 229960002386 prazosin hydrochloride Drugs 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004259 prednisolone tebutate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
- 229960002393 primidone Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960005439 propantheline bromide Drugs 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 229960001187 propiverine hydrochloride Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 1
- 201000007608 radiation cystitis Diseases 0.000 description 1
- 229950004496 ramatroban Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- DSDNAKHZNJAGHN-UHFFFAOYSA-N resinferatoxin Natural products C1=C(O)C(OC)=CC(CC(=O)OCC=2CC3(O)C(=O)C(C)=CC3C34C(C)CC5(OC(O4)(CC=4C=CC=CC=4)OC5C3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-UHFFFAOYSA-N 0.000 description 1
- DSDNAKHZNJAGHN-MXTYGGKSSA-N resiniferatoxin Chemical compound C1=C(O)C(OC)=CC(CC(=O)OCC=2C[C@]3(O)C(=O)C(C)=C[C@H]3[C@@]34[C@H](C)C[C@@]5(O[C@@](O4)(CC=4C=CC=CC=4)O[C@@H]5[C@@H]3C=2)C(C)=C)=C1 DSDNAKHZNJAGHN-MXTYGGKSSA-N 0.000 description 1
- 229940073454 resiniferatoxin Drugs 0.000 description 1
- 229950009846 scopolamine butylbromide Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229960003090 seratrodast Drugs 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 1
- 229940039790 sodium oxalate Drugs 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 229940084026 sodium valproate Drugs 0.000 description 1
- 229960003855 solifenacin Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 229950011082 suplatast tosilate Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003198 tamsulosin hydrochloride Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950011558 tazanolast Drugs 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N tenoxicam Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960000351 terfenadine Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 125000005063 tetradecenyl group Chemical group C(=CCCCCCCCCCCCC)* 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- ZYXWYDDFNXBTFO-UHFFFAOYSA-N tetrazolidine Chemical compound C1NNNN1 ZYXWYDDFNXBTFO-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- BXVYJQULAWJPSR-UHFFFAOYSA-N thiadiazepine Chemical compound S1C=CC=CN=N1 BXVYJQULAWJPSR-UHFFFAOYSA-N 0.000 description 1
- TVQOEGVBMRCMFR-UHFFFAOYSA-N thiadiazinane Chemical compound C1CNNSC1 TVQOEGVBMRCMFR-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- PGAZQSBUJDVGIX-UHFFFAOYSA-N thiazepane Chemical compound C1CCNSCC1 PGAZQSBUJDVGIX-UHFFFAOYSA-N 0.000 description 1
- NYERMPLPURRVGM-UHFFFAOYSA-N thiazepine Chemical compound S1C=CC=CC=N1 NYERMPLPURRVGM-UHFFFAOYSA-N 0.000 description 1
- AJZGFFKDLABHDD-UHFFFAOYSA-N thiazinane Chemical compound C1CCSNC1 AJZGFFKDLABHDD-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- 229960003553 tolterodine tartrate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000000169 tricyclic heterocycle group Chemical group 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 229960002835 trimipramine maleate Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960001530 trospium chloride Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- RSJKGSCJYJTIGS-BJUDXGSMSA-N undecane Chemical group CCCCCCCCCC[11CH3] RSJKGSCJYJTIGS-BJUDXGSMSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 201000001988 urethral stricture Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229950004227 zaltoprofen Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention comprises EP 4 agonist useful as a medicine (1) preventive or therapeutic agent for lower urinary tract disease, (2) bladder capacity or bladder compliance And (3) an agent for protecting the bladder mucosa and / or bladder epithelial cells and promoting Z or regeneration.
- Lower urinary tract disease is a disorder in the bladder and its drainage tract that is recognized and diagnosed as a lower urinary tract symptom.
- Lower urinary tract symptoms are categorized into urination symptoms, post urination symptoms, urinary storage symptoms, genital and / or lower urinary tract pain.
- Urination symptoms are symptoms in the urination phase, such as urinary dysfunction, urinary division, urinary disruption, urination delay, abdominal pressure urination, and terminal dropping.
- Post-urinary symptoms are symptoms that occur immediately after urination, such as residual urine sensation and post-urine dripping.
- Urinary symptom refers to symptoms such as daytime frequent urination, nighttime frequent urination, urgency of urine, urinary incontinence, increased or decreased bladder perception.
- Genital and Z or lower urinary tract pain includes bladder pain, urethral pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain.
- causes of lower urinary tract symptoms are: (1) spinal cord injury, cerebrospinal tumor, cerebrospinal vascular disorder, myelitis, multiple sclerosis, Parkinson's disease, spinal meningocele, uterine cancer radical surgery, rectal cancer radical surgery Disorders of the nerves that control the bladder and Z or urethral sphincter, etc. due to (2) cystitis, prostatitis, lower ureteral stones, irritation to the bladder mucosa by bladder wall lesions such as bladder cancer, bladder muscle layer Inflammation or fibrosis, (3) urethral sphincter damage, (4) prostatic hypertrophy, prostate cancer, bladder neck sclerosis, urethral stricture, etc. Presence of obstructive lesions of the urethra due to. Treatment is based on the treatment of each causative disorder, but if that is not possible, symptomatic treatment is performed.
- Cystitis a lower urinary tract disease
- Cystitis is primarily an infectious or non-infectious inflammation in the bladder mucosa and submucosa, but sometimes extends to the muscle layer.
- it is classified into acute cystitis and chronic cystitis according to the clinical course, and is classified into simple cystitis and complicated cystitis according to the presence or absence of obstructive disease of the lower urinary tract.
- simple cystitis is acute and responds well to antibiotics, but complex cystitis is chronic and often difficult to respond to antibiotics, which are refractory cystitis Sometimes called.
- Refractory cystitis is called primary interstitial cystitis when the cause cannot be identified, whereas interstitial cystitis with the causes described in (1) to (5) below, Bacterial refractory cystitis, hemorrhagic cystitis, eosinophilic cystitis, etc. are called secondary interstitial cystitis.
- Bacterial tuberculosis is representative of bacterial refractory cystitis.
- Bladder tuberculosis is a strong bladder inflammatory condition and the power of pyouria Normal antibiotics are ineffective.
- Hemorrhagic cystitis is cystitis with the main complaint of strong hematuria, the cause of which varies and is not a single disease.
- the main causes are: (1) viruses such as adenovirus and influenza virus, (2) bacteria and other microorganisms such as E.
- primary interstitial cystitis refers to severe frequent urination (for example, urination about 6 to 70 times a day may be necessary) and urinary storage symptoms such as urgency, urinary bladder It is positioned as a chronic inflammatory disease of the bladder interstitium of unknown origin without urinary tract infection or specific pathological findings, mainly due to genital and / or lower urinary tract pain and discomfort during and after urination It has been.
- NASH National Institute of Health
- GAG glycosylaminoglycan
- hepatic preparations with the expectation of hydroexpansion that mechanically expands the fibrotic and contracted bladder, mucosal repair, anti-inflammatory action, anti-allergic action, C-fiber activation suppression, dimethyl
- Intravesical infusion treatments such as sulfoxide preparations, hyaluronic acid preparations, resin ferritoxin preparations, and botulinum toxin preparations are performed.
- the improvement of symptoms by anticholinergic drugs, a frequent urination drug that suppresses bladder smooth muscle movement is exceptional, and heparinanaguchi pentoic acid polysulfate in anticipation of mucosal repair, anti-inflammatory action, etc.
- Anti-depressant, analgesic 'anti-inflammatory, anti-convulsant, anti-histamine and anti-allergic drug in anticipation of administration of sodium (Elmiron: registered trademark), analgesic action, anti-inflammatory action, anti-allergic action, etc.
- analgesic action anti-inflammatory action, anti-allergic action, etc.
- no useful therapeutic drug has been found yet.
- prostaglandin (PG) E 2 is known as a metabolite in the arachidonic acid cascade. It is known to have various physiological and pharmacological functions such as action, blood pressure lowering action, and diuretic action.
- EP 4 agonist does not show hyperurination in the lower urinary tract disease model induced by cyclophosphamide and improves its frequent urination symptoms that, (2) and EP 3 ⁇ GORE - When the scan bets to bladder ⁇ input, since the bladder irritation is induced, in particular, selective EP 4 ⁇ GORE - with the strike, no side effects lower (3) EP 4 agonist is useful for preventing and / or treating urinary tract diseases. They found improved bladder compliance, and (4) EP 4 agonists found to protect and / or promote regeneration of bladder mucosa and Z or bladder epithelial cells, completing the present invention.
- An agent for improving bladder compliance and Z or bladder capacity comprising EP 4 agonist
- EP 4 agonist and heparin formulation dimethyl sulfoxide formulation, hyaluronic acid formulation, rejuferatoxin formulation, botulinum 'toxin formulation, sodium pentasulfate formulation, antidepressant, antibiotic, analgesic' anti-inflammatory drug, Anticonvulsant
- EP 4 is the general formula (I)
- T represents an oxygen atom, a halogen atom or an optionally substituted acyloxy group
- R 1 represents a hydrogen atom, a hydroxyl group, a C 1-6 alkyloxy group, or a C 1-6 acyloxy group.
- U represents an oxygen atom or a sulfur atom
- X and Y each independently represents a methylene group, an oxygen atom, a sulfur atom or a nitrogen atom which may have a substituent, but X and Y are simultaneously Represents an oxygen atom, a sulfur atom or a nitrogen atom which may have a substituent
- A represents a spacer having 1 to 8 atoms in the main chain which may have a substituent.
- D represents an optionally protected acidic group
- R 2 and R 3 each independently represents an optionally substituted alkyle group or a halogen atom
- R 4 represents a substituent.
- Z represents one configuration or J3—configuration or a mixture of any proportions thereof.
- the EP 4 agonist has the general formula (IA)
- R 19A and R 2DA each independently represent (1) a hydrogen atom, (2) a C 1-10 alkyl group, or ( 3) represents a halogen atom
- T A represents (1) an oxygen atom or (2) a sulfur atom
- X A represents (1) one CH 2 — group, (2) — O— group, or (3) — S— represents a group
- a A represents A 1A or A 2A
- a 1A is (1) a linear C 2-8 alkylene group optionally substituted by 1 to 2 C 1-4 alkyl groups , (2) linear C 2-8 alkenylene group optionally substituted with 1-2 C 1-4 alkyl groups, or (3) substituted with 1-2 C 1-4 alkyl groups
- a 2A represents one G 1 A — G 2A — G 3A — group
- 0 represents (1) 1-2.
- R 3A represents (1) a hydrogen atom or (2) C 1 to 10 alkyl group
- R 4A represents (1) C 1-10 alkyl group or (2) phenol group
- D represents (1) —CH 2 OH group, (2) —CH 2 OR 5 A group, (3) hydroxyl group, (4) —OR 5A group, (5) formyl group, (6) —CONR 6A R 7A group, (7) —C ONR 6A S0 2 R 8A group, (8) —CO — (NH—amino acid residue—CO) mA — OH3 ⁇ 4, (9) —O— (CO—amino acid residue—NH)
- R 5A represents a C 1-10 alkyl group
- R 6A and R 7A each independently represent (1) a hydrogen atom or (2) a C 1-10 alkyl group
- R 8A represents R 9A represents a C 1-10 alkyl group substituted with a ru group
- R 9A may be (1) 1 to 3 C 1-10 alkyl groups, C 1-10 alkoxy groups or a halogen atom.
- R 1 () A represents (1) a phenol group or (2) a C 1-10 alkyl group, mA represents 1 or 2, Z 1A represents (1) a C 1-15 alkylene group, (2) C 2-15 alkenylene group, or (3) C 2-15 alkynylene group, Z 2 A is (1) —CO— group, (2) —OCO—group> (3) —COO— group , (4) —CO NR 11A — group, (5) — NR 12A CO— group, (6) — O— group, (7) — S— group, (8) — SO single group, (9) —SO 2 — group, (10 ) — NR 13A — group, (11) one NR 14A CONR 15A — group, (12) — NR 16A COO— group, (13) — OCONR 17A — group, or (14) — OCOO represents one group, Z 3 A is (1) hydrogen atom, (2) C 1-15 alkyl group, (3) C 2-15 alkenyl group, (4) C 2-15
- R 27A is (1) Represents a hydrogen atom or (2) a C 1-10 alkyl group, ring 1 A , ring 2 A , ring 5 A , ring 6 A , and ring 7 A may be (1) partially or fully saturated C 3-15 monocyclic, bicyclic or tricyclic carbocyclic aryl, or (2) containing 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur atoms, part or Represents a 3- to 15-membered monocyclic, bicyclic or tricyclic heteroaryl which may be fully saturated, ring 3 A and ring 4 A are: (1) a phenyl group, (2) a phenol Group, or (3) represents a furyl group, ring 6 A and ring 7 A are; May be substituted with up to 3 R 28A , and R 28A may
- T A is an oxygen atom
- X A is a —CH 2 — group
- a A represents A 1A
- D A represents D 1A
- E A represents E 2A
- ring 5 A does not represent a C 3-7 cycloalkyl group, a phenyl group, a phenyl group, or a furyl group
- ring 6 A represents a phenyl group, at least one phenyl group Of R 28A .
- Compounds represented by] a salt thereof, N- Okishido thereof or a solvate thereof, or a prodrug, or agent of the 1, 8 or 9 wherein the cyclodextrin clathrates thereof, 13.
- R 1B represents hydroxy, C ⁇ -6 alkyloxy, or NR 6B R 7B group (wherein R 6B and R 7B independently represent a hydrogen atom or C 1-4 alkyl).
- R 2B is an oxygen atom, halogen atom or O—COR 8B group (in the group,
- R 8B represents C 1-4 alkyl, phenyl or phenyl (C 1-4 alkyl).
- R 3B represents a hydrogen atom or hydroxy
- R 4aB and R 4 bB each independently represent a hydrogen atom or C 1-4 alkyl
- R 5B is a phenyl substituted with the following groups: Represents the group:
- cycloalkyl (C 1-4 alkyloxy) 1 C 1-4 alkyl, (0 phenyloxy C 1-4 alkyl, (g) phenyl C 1-4 alkyloxy — C 1-4 alkyl, (h) C 1-4 alkylthio-one C 1-4 alkyl, i) C 2 -4 alkenylthio mono C1-4 alkynole, (j) C2-4 alkynylthio mono C1-4 alkyl, (k) C3-7 cycloalkylthio mono C1-4 alkyl, 0) C3-7 cyclo Alkyl (C1-4 alkylthio) 1 C1-4 alkyl, (m) phenylthio1 C1-4 alkyl, or (n) phenoly C1-4 alkylthio1 C1-4 alkynole,
- a method for improving bladder compliance and / or bladder capacity characterized by administering an effective amount of EP 4 agonist to a mammal during the lactation period,
- a method for protecting and / or promoting regeneration of bladder mucosa and / or bladder epithelial cells characterized by administering an effective amount of EP 4 agonist to a mammal,
- EP 4 agonist to produce an agent for protecting and / or promoting regeneration of bladder mucosa and / or bladder epithelial cells.
- examples of the “cyclic group” in the “cyclic group optionally having substituent (s)” represented by R 4 include a carbocycle or a heterocycle.
- examples of the carbon ring include C 3 to 15 monocyclic or polycyclic carbocycles, spiro-bonded polycyclic carbocycles or bridged polycyclic carbocycles.
- C 3-15 monocyclic or polycyclic carbocycles include C 3-15 monocyclic or polycyclic unsaturated carbocycles, carbocycles that are partially or fully saturated.
- -Hydroazulene indene, perhydroindene, indane, naphthalene, dihydronaphthalene, tetrahydronaphthalene, perhydronaphthalene, heptalene, hydrohydroheptalene, biphenylene, as-indacene, s— Examples include dasene, isanaphthylene, isanaphthene, fluorene, phenalene, phenanthrene, and anthracene ring. Examples of spiro-linked polycyclic carbocycles include spiro [4. 4] nonane, spiro [4. 5] decane, spiro [5.
- bridged polycyclic carbocycles include bicyclo [2. 2. 1] heptane, bicyclo [2. 2. 1] heptane 2-en, bicyclo [3. 1. 1] heptane, bicyclo [3 1. 1] Hepta-2-en, Bicyclo [3. 2. 1] Octane, Bicyclo [2. 2. 2] Octane, Bicyclo [2. 2. 2] Talented 2—Yen, Adamantane, Examples include a nordamantane ring.
- examples of the C 3-15 monocyclic or polycyclic aromatic carbocyclic ring include benzene, azulene, naphthalene, futanal, and anthracene ring.
- examples of the heterocyclic ring include, for example, a 3 to 15-membered monocyclic or polycyclic heterocyclic ring containing 1 to 5 heteroatoms selected from an oxygen atom, a nitrogen atom and / or a sulfur atom, and a spiro bond.
- examples include polycyclic heterocycles and bridged polycyclic heterocycles.
- a 3- to 15-membered monocyclic or polycyclic heterocyclic ring containing 1 to 5 heteroatoms selected from oxygen, nitrogen and / or sulfur atoms includes oxygen, nitrogen and / or sulfur.
- 3 to 15 membered monocyclic or polycyclic unsaturated heterocycles containing 1 to 5 heteroatoms selected from yellow atoms, and heterocycles partially or fully saturated are included.
- spiro-linked bicyclic heterocycles examples include azaspiro [4.4] nonane, azaspiro [4.5] decane, azaspiro [5.5] undecane ring, and the like.
- Bridged bicyclic heterocycles include, for example, azabicyclo [2.2.1] heptane, azabicyclo [3. 1. 1] heptane, azabicyclo [3.2.1] octane, azabicyclo [2 2. 2] Examples include octane ring.
- a 3 to 15-membered monocyclic, bicyclic or tricyclic aromatic heterocycle containing 1 to 5 heteroatoms selected from an oxygen atom, nitrogen atom, Z or sulfur atom For example, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, brazan, oxadiazonole, thiadiazonole, indonorole, isoinole Orchid, isobenzofuran, benzothiophene, isobenzothiophene, indazole, quinoline, isoquinoline, purine, phthalazine, pteridine, naphthyridine, quinoxaline, quinazoline, cinnoline, benzoxazolone, ben Chiazo
- Examples of the “substituent” in the “cyclic group optionally having substituent (s)” represented by R 4 include (a) an alkyl group optionally having substituent (s), and (b) having a substituent. (C) an alkyl group which may have a substituent, (d) a carbocyclic group which may have a substituent, and (e) a substituent.
- examples of the ⁇ kill group '' include methyl, ethyl, propyl, isopropyl, propyl, isoptinole, sec-petitzole, tert-butinole, pentyl, isopentyl, nepentyl pentinole, hexyl, heptyl, octyl, noel, decyl, undecyl, Examples thereof include linear or branched C 1-15 alkyl groups such as dodecyl, tridecyl, tetradecyl and pentadecyl groups.
- the substituent of the alkyl group includes a hydroxyl group, an amino group, a carboxynole group, a cyano group, a nitro group, a mono- or di-C 1-10 alkylamino group (for example, methylamino, ethylamino, propinoreamino, dimethinoreamino, jetinoreamino, etc. ), C 1-10 alkoxy group (for example, methoxy, ethoxy, propoxy, isopropoxy, t-butoxy, hexyloxy, octyloxy, decanyloxy, etc.), c
- acyloxy groups eg, acetyloxy, ethanolyloxy, propanoinoreoxy, butanoinoreoxy, pentanoinoreoxy, hexanoinoleoxy group, etc.
- C 1-10 alkylcarbonyloxy groups eg, acetooxy, ethylcarbonyl) Xy, etc.
- carbocyclic ring represents the same meaning as the carbocyclic ring in the “cyclic group” in the “cyclic group optionally having substituents” It represents the same meaning as the heterocyclic ring in the “cyclic group” in the “optionally selected cyclic group.”
- Halogen atom the same meaning as described above
- substituted with 1 to 3 halogen atoms C 1-10 alkoxy group for example, monofluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, etc.
- —O-carbocycle (as described above Represents the same meaning as the carb
- alkenyl group in the “alkenyl group optionally having substituent (s)” as the substituent include, for example, ether, propenyl, butyr, and pageage. 2 / Le, Pentenole, Pentagenore, Hexeninore, Hexageninore, Hepte Ninore, Heptajenore, Otathenore, Octagenore, Nonnunore, Nonageninore, Deceninore, Decadenisenore, Undecenide And straight chain or branched C 2-15 alkyl group such as a group.
- the substituent of the alkyl group has the same meaning as the substituent in the above-mentioned “alkyl group optionally having substituent (s)”.
- Examples of the “anolecule / le group” in the “alkyl group optionally having substituent (s)” as the substituent include, for example, ethu ⁇ propie ⁇ /, butche ⁇ ⁇ , ptazinyore, pentunore, pentadienore, Hexnore, Hexazininole, Heptininore, Heptaziye 7le, Otache Nore, Octajininore, Nonininore, Nonazinyl, Decynyl, Decadiel, Undecinizore, Dodecinore, Tridecynole, Tetradecenyl Alternatively, branched C 2 to 15 ′ alkyl groups and the like can be mentioned.
- the substituent of the alkyl group has the same meaning as the substituent in the above-mentioned “alkyl group optionally having substituent (s)”.
- the carbocyclic ring in the “optionally substituted carbocyclic group” as the substituent is the carbocyclic ring in the “cyclic group” in the aforementioned “optionally substituted cyclic group”. Means the same.
- the substituent of the carbocycle for example, a linear or branched C 1-15 alkyl group (the same meaning as the alkyl group in the above-mentioned “alkyl group which may have a substituent”) may be used. ), Linear or branched C.
- alkyl group (the same meaning as the alkenyl group in the above-mentioned “alkyl group which may have a substituent”), linear Or a branched C 2 to 15 alkynole group (which has the same meaning as the alkynyl group in the “optionally substituted alkynyl group”), a hydroxyl group, a C 1-6 alkoxy group ( For example, methoxy, ethoxy, propoxy, isopropoxy, ptoxy, isobutyloxy, tert-butoxy, pentyloxy, hexyloxy, etc.), thiol group, C1-6 alkylthio group (for example, methylthio, ethylthio, propyl) Pyrthio, isopropylthio, butylthio, isobutylthio, tert-butinoretio, pentylthio, hexylthio, etc.), amino group, monon
- heterocyclic ring in the “optionally substituted heterocyclic group” as the substituent is the heterocyclic ring in the “cyclic group” in the aforementioned “optionally substituted cyclic group”. Means the same.
- the substituent of the heterocyclic ring has the same meaning as the substituent in the above-described “'carbocyclic group optionally having substituent”.
- Examples of the compound include: (i) an optionally substituted alkyl group (having the same meaning as described above), (ii) an optionally substituted alkenyl group (as described above) ), ( ⁇ ) Alkynyl group which may have a substituent (same meaning as described above), (iv) Carbocyclic group which may have a substituent ( (V) a heterocyclic group which may have a substituent (same meaning as described above), (vi) an acyl group (for example, formyl, Acetyl, propanoyl, bivalloyl, butanol, pentanoyl, hexanoyl C 1-6 alkanoyl groups such as isomers thereof, C 6-10 aromatic carbocycl
- Examples of the “optionally substituted rubamoyl group” as a substituent include an unsubstituted rubamoyl group, N-mono-C 1-6 alkyl rubamoyl (for example, N-methylcarbamoyl, N— Tylcarbamoyl, N-propylcarpamoinole, N-Isopropinorecanolevamoy / Le, N-Putinorecanolevamoinole, N-Isoptylcarbamoyl, N- (tert-butyl) Force rubermoyl, N-pentyl N-hexylcarbamoyl, etc.), N-mono-carbamoinole, etc., N-mono-C 6-10 valinole force / levamoinole, N, N-di C 1-6 aranolyl-kill force rubamoyl (eg, N, N-dimethylcarbam
- Examples of the “optionally substituted sulfamoyl group” as the substituent include an unsubstituted sulfamoyl group, N-mono-C 1-6 alkylsulfamoyl (for example, N-methylsulfamoyl, N —Ethylsulfamoyl, N-propylsulfamoyl, N-isopropylsulfamoyl, N-butylsulfamoinole, N—Isopti / Les / Lefamoinole, N— (tert-Butinole) Xylsulfamoyl etc.), N— N-mono-C 6-1 0 allyres norefa moinole, such as Fuenores norefamoire.
- N-mono-C 1-6 alkylsulfamoyl for example, N-methylsulfamoyl, N —Ethylsulfam
- N, N-di-C 1-6 alkylsulfamoyl for example, N, N-dimethyls norefamoinole, N, N-jeti / resnorefamoinole, N, N-dipropinolesnore famoyl, N, N-dibutylsulfamoyl, N, N-dipentylsulfamoyl, N, N-dihexylsulfamoyl, N N-G C 6-10 aryl sulfamoyl, N-C 6-10 aryl sulfamoyl, etc.
- N, N-di-C 1-6 alkylsulfamoyl for example, N, N-dimethyls norefamoinole, N, N-jeti / resnorefamoinole, N, N-dipropinolesnore famoyl, N
- N-C 1-6 alkyl sulfa Moyl eg N-phenyl-N-methylsulfamoyl, N-phenyl-1-N-ethylsulfamoyl, N-phenyl-1-N-propylsulfamoyl, N-phenyl-1-N-butylsulfamoyl, N-phenyl
- One N-pentinolesulfamoyl N-phenyl-1-N-hexylsulfamoyl, etc.
- the "aliphatic hydrocarbon group optionally having substituent (s)" represented by R 4 includes, for example, an alkyl group optionally having substituent (s), substituent (s) Represents an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, etc., wherein “an alkyl group which may have a substituent” or “has a substituent.
- the “optional alkyl group” or the “alkyl group optionally having substituent (s)” is the “alkyl group optionally having substituent (s)” defined in the substituent in the aforementioned cyclic group,
- an alkenyl group optionally having a substituent” or “an alkynyl group optionally having a substituent” is represented.
- examples of the “C 1-6 alkyloxy group” represented by R 1 include methoxy, ethoxy, propoxy, butoxy, pent / reoxy, hexoxy groups and the like.
- examples of the “C 1-6 acyloxy group” represented by R 1 include acetyloxy, ethanoyloxy, propanoyloxy, butanoyloxy, pentanoyloxy, hexanoyloxy groups and the like.
- the “optionally substituted alkyl group” represented by R 2 or R 3 is defined as the “optionally substituted alkyl group” defined in the above-mentioned R 4 . The same meaning as "
- halogen atom represented by R 2 or R 3 represents the same meaning as described above.
- the “acyloxy group in the optionally substituted acyloxy group j represented by T” includes, for example, C 1-10 alkanoyloxy such as acetyloxy, propanoyloxy, bivalyloxy and the like. Groups and the like.
- the “substituent” in the “optionally substituted acyloxy group” represented by T is the substituent in the “optionally substituted alkyl group” defined in R 4 described above. Represents the same meaning as the group.
- the “substituent” in the “nitrogen atom optionally having substituent (s)” represented by X and Y is “alkyl group optionally having substituent (s)” or “ A cyclic group optionally having substituent (s), wherein the “alkyl group optionally having substituent (s)” or “cyclic group optionally having substituent (s)” in R 4 It has the same meaning as the defined “alkyl group optionally having substituent (s)” or “cyclic group optionally having substituent (s)”.
- the “spacer having 1 to 8 atoms in the main chain” in the “spacer having 1 to 8 atoms in the main chain which may have a substituent” represented by A Means the interval between 1 to 8 atoms.
- “the number of atoms in the main chain” is counted so that the atoms in the main chain are minimized.
- the number of atoms of 1,4 or 1 is 4 and the number of atoms of 1,3—phenylene is 3.
- Examples of the “spacer having 1 to 8 atoms in the main chain” include C 1-8 alkylene, C 2-8 alkenylene group, C 2-8 alkynylene group, cyclic group, etc.
- the carbon atoms in these groups are replaced by 1-5 oxygen, nitrogen, sulfur, force, thiocarbol, sulbuyl, and sulfonyl groups at structurally possible positions. It may be.
- Examples of the C 1-8 alkylene group include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, otatamethylene group and the like.
- Examples of the C 2-8 alkenylene group include, for example, etylene, propenylene, ptenylene, ptagenelene, pentulene, pentageylene, hexenylene, hexagenylene, heptenylene, heptagenelene, otaterylene, octagenylene group, etc. Is mentioned.
- C 2-8 alkylene groups include, for example, ethynylene, propylene, petitylene, butazinylene, pentylene, pentadiylene, hexylene, hexazinylene, heptylene, heptadylene, octylene. And octadinylene group.
- the “cyclic group” has the same meaning as the “cyclic group” in the “cyclic group optionally having substituent (s)” defined in R 4 described above.
- the “substituent” represented by the “spacer having 1 to 8 atoms in the main chain which may have a substituent” is the above-mentioned “alkyl group which may have a substituent”. It has the same meaning as “substituent”. These optional substituents may be substituted at substitutable positions of 1 to 10, preferably 1 to 5, more preferably 1 to 3.
- the “optionally protected acidic group” represented by D represents an “acidic group” which may be protected by a “protective group”.
- the “acidic group” include: , (A) hydroxyl group, (b) formyl group (-CHO), (c) alkoxy group (for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutyoxy, tert-butoxy, pentyloxy, hexyloxy, etc. 1-6 alkoxy groups, C 6-10 aryloxy groups such as phenoxy, etc.), (d) carboxyl groups (—COOH), (e) sulfo groups (one SO 3 H), (0 sulfonamides (one SO. NH.
- R 1Q1 has a hydrogen atom or a substituent.
- an alkyl group which may have the same meaning as the “alkyl group optionally having substituent (s)” defined in R 4 described above. )), (G) Phosphono group
- “Bronsted acid” refers to a substance that gives hydrogen ions to other substances. Examples of the "nitrogen-containing ring residue having a hydrogen atom that can be deprotonated” include
- Suitable “acidic groups” include a carboxyl group or a hydroxyl group. More preferably, a carboxyl group is mentioned.
- the “protecting group” in the “optionally protected acidic group” represented by D includes (a) an optionally substituted alkyl group (the “substituted group defined in R 4 described above”). The same meaning as “an alkyl group which may have a group” is represented.), (B) a cyclic group which may have a substituent (which may have a substituent as defined in R 4 described above) It represents the same meaning as “good cyclic group”. ), (C) Amino group optionally having substituent (s)
- amino acid means an amino acid residue of a natural amino acid or non-natural amino acid
- the natural amino acid or abnormal amino acid includes, for example, glycine, alanine, parin, leucine, isoleucine, serine, Threonine, Cystine, Methionine, Proline, Asparagine, Gnoretamine, Phenololealanine, Tyrosine, Tryptophan, Ryo Spartic acid, Glutamic acid, Lysine, Argyyun, Histidine, ⁇ -arayun, Cistachioyun, Cystine, Homoserine, Lonelysin Nonoleucine, Nonorevaline, Onorenitine, Sanorecosin, Tyronin and the like.
- this amino acid contains an amino group, those in which the amino group is substituted with a substituent of the amino group described above are also included.
- R 19A and R 2Q A each independently represents (1) a hydrogen atom, (2) a C 1-10 alkyl group, or (3) represents a halogen atom
- T A represents (1) an oxygen atom or (2) a sulfur atom
- X A represents (1) one CH 2 — group, (2) —0— group, or ( 3) represents an —S— group
- a A represents A 1A or A 2A
- a 1A is (1) linear C 2 which may be substituted with 1 to 2 C 1-4 alkyl groups ⁇ 8 alkylene group, (2) a linear C 2-8 alkenylene group optionally substituted with 1 to 2 ⁇ 1-4 alkyl groups, or (3) 1 to 2 C 1-4 alkyls Represents a linear C 2-8 alkylene group which may be substituted with a group
- a 2A represents one G 1A —G 2A — G 3A — group
- G 1A represents (1) 1-2 C 1 Linear C 1-4 alkylene group
- R 3A represents S0 2 R 4A group
- R 2A represents (1) C 1 to: L 0 alkyl group, (2) phenol group, and (3) C 1 to 10 alkyl group substituted with a phenol group.
- (4) represents a biphenyl group
- R 3A represents (1) a hydrogen atom or (2) a C 1-10 alkyl group
- R 4A represents (1) a C 1-10 alkyl group or (2) phenyl.
- D 2A represents (1) —CH 2 OH group, (2) —CH 2 OR 5A group, (3) hydroxyl group, (4) one OR 5A group, (5) formyl group, (6) — CONR 6A R 7A group, (7) — CONR 6A S0 2 R 8A group, (8) — CO— (NH—amino acid residue—one CO) mA — OH group, (9) — O— (CO— 1 amino acid residue NH) mA — H group, (10) — COOR 9A group, (11) -00—1 1 group, (12) — COO— Z 1A — Z 2 A — Z 3A group, (13 )
- R 5A represents a C 1-10 alkyl group
- R 6A and R 7A each independently represent (1) a hydrogen atom or (2) a C 1-10 alkyl group
- R 8A represents a fuel group. Represents a C 1-10 alkyl group substituted with R 9A (1) 1 to 3 ⁇ 1 ⁇
- R 11A , R 12A , R 13A , R 14A , R 15A , R 16A , R 17A and R 18A each independently represent (1) a hydrogen atom or (2) a C 1-15 alkyl group
- R 11A and Z 3 A together with the nitrogen atom to which the group is attached may represent a 5- to 7-membered monocyclic saturated heterocycle, which further includes an oxygen atom, a nitrogen atom and a sulfur atom. It may contain one heteroatom selected from the atoms, E A represents E 1A or E 2 A, E 1A is (1) a C 3-7 cycloalkyl group, or (2) ring 3 represents a, E 2A is (1) C.
- Ring 3 A may be substituted with 1 to 2 R 21A
- C 3-7 cyclohexane represented by E 2 A may be substituted with R 21A and Z or R 22A.
- alkyl group is always substituted with one R 21A or R 22A, is In 1-2 or R 21A and Z may be substituted with R 22A, ring 4 A is always substituted with one R 22A, further 1-2 R 21A and Z or R 22A
- the ring represented by the nitrogen atom to which R 11 A and the Z 3 A group are bonded, or ring 2 A may be substituted with R 23A
- R 21A is (1) C 1-10 alkyl group, (2) C 1-10 alkoxy group, (3) halogen atom, (4) ether group, (5) C substituted with 1 to 3 halogen atoms 1 to 10 alkyl group, or (6) represents a full group
- R 22A represents (1) C 2 to 10 alkenyl group, (2) C 2 to: L 0 alkyl group, (3) C 1 to: L 0 alkylthio group, (4) hydroxyl group, (5) —NR 24 AR 25 A group, (6) C 1-10 alkyl group substituted with C 1-10 alkoxy group,
- R 24A , R 25A and R 26A Each independently represents (1) a hydrogen atom or (2) a C 1-10 alkyl group, R 23A is (1) a C 1-15 alkyl group, (2) a C 2-15 alkyl group, (3) a C 2-15 alkyl group, or (4) a C 1-10 alkoxy group, a C 1-10 alkylthio group, or a C 1-10 alkyl-NR 27A — group substituted with a C 1-10 alkyl group.
- R 27A represents (1) a hydrogen atom or (2) a C 1-10 alkyl group
- ringl A , ring 2 A , ring 5 A , ring 6 A , and ring 7 A are (1) -parts or All may be saturated C 3-15 monocyclic, bicyclic Or a tricyclic carbocyclic aryl, or (2) part or all of which may contain 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur atoms may be saturated 3 to Represents a 15-membered monocyclic, bicyclic or tricyclic heteroaryl
- ring 3 A and ring 4 A represent (1) a chayl group, (2) a phenyl group, or (3) a furyl group
- Ring 6 A , and ring 7 A may be substituted with 1 to 3 R 28A s , where R 28A is (1) C 1: L 0 alkyl group, (2) C 2: L 0 Alqueel Group, (3) C 2-10 alkynyl group, (4) C 1-10 alkoxy
- T A is an oxygen atom
- X A is a —CH 2 — group
- a A represents A 1A
- D A represents D 1A
- E A represents E 2A
- R 1B represents hydroxy, C 1-6 alkyloxy, or NR 6B R 7B group (wherein R 6B and R 7B independently represent a hydrogen atom or C 1-4 alkyl).
- R 2B represents an oxygen atom, a halogen atom or an O—COR 8B group (wherein R 8B represents C 1-4 alkyl, phenol or phenol (C 1-4 alkyl)).
- R 3B represents a hydrogen atom or hydroxy
- R 4aB and R 4 b B each independently represent a hydrogen atom or C 1-4 alkyl
- R 5B represents the following i) to iv): Represents a substituted Hue- / Rh group:
- 1-4 alkyl (1) C 1-4 alkyl, (h) C 1-4 alkylthio C 1-4 alkyl, i) C 2-4 A 7 Rec 7 7 Reciol C 1-4 Alky / L, j) C 2-4 Alkylthio—C 1-4 Alkyl, (k) C 3-7 Cycloalkylthio—C 1-4 Alkyl, d) C 3-7 cycloalkyl (C 1-4 alkylthio) mono C 1-4 alkyl, (m) phenylthio C 1-4 alkyl, or (n) fur C 1-4 alkylthio C 1-4 alkyl,
- European Patent Application No. 855389 describes that a compound represented by the following general formula (IC) has an EP 4 agonist action.
- the definition of each group of the compound represented by the general formula (IC) is described in detail in European Patent Application Publication No. 855389. Therefore, as my EP 4 Is the general formula (I c)
- R 1C represents a hydroxyl group, C 1-4 alkoxy or NR 6C R 7C (wherein R 6C and R 7 c independently represent a hydrogen atom or a C 1-4 alkyl group) Represents
- R 2 c represents a hydrogen atom or a hydroxyl group
- R 3C is (i) C 1-8 alkyl, C 2-8 alkenyl, or C 2-8 alkynyl group, (ii) phenol or C 3-7 cycloalkyl group, (iii) fuel or C 3 7 C 1-8 alkyl, C 2-8 alkelle, or C 2-8 alkynyl group substituted with a cycloalkyl group (provided that when R 2C is a hydrogen atom, the alkyl of (i) and (iii), An alkiel group or an alkiel group may be substituted with one hydroxyl group, and represents a double bond or a single bond. However, it includes the 8-epide which is an equilibrium compound. ]
- R 1D represents hydroxy, C 1-6 alkyloxy or NR 6D R 7D (wherein R 6D and R 7D independently represent a hydrogen atom or C 1-6 alkyl) Represents;
- R 2D represents a hydrogen atom or hydroxy
- R 3D represents a single bond or C 1-6 alkylene
- R 5 D represents a hydrogen atom or C 1-6 alkyl
- R 2 D is a hydrogen atom
- C 1-6 alkylene represented by R 3 D may be substituted with one hydroxy.
- a E represents C 2-8 alkylene, C 2-8 alkenylene, C 1-4 alkylene monophenylene, or C 2-4 alkenylene monophenylene, R 1E represents hydroxy, C l -6 alkyloxy, C1-6 alkyloxy 1 C 1-6 alkyloxy, HO-C 1-6 alkyloxy, or NR 6E R 7E where R 6E and R 7E are independently a hydrogen atom or C 1-6 4 represents alkyl)
- R 2E is an oxygen atom, a halogen atom or R 8E — COO— (wherein R 8E is a hydrogen atom, C 1-4 alkyl, fuel or ferrule (C 1-4 alkyl), C 1-4 Alkyloxy, HOOC-C1-4 alkyl, C1-4 alkyloxy-carbol—C1-4 alkyl, HOOC—C2-4 alkenyl, or C1-4 alkyloxy-carboluro C2-4 alkyle.) 'R 3E represents a hydrogen atom or hydroxy,
- R 4E represents C 1-4 alkylene
- R 5E represents a phenyl group substituted with the following i) to iv) groups: i) 1 to 3 (1) C 1-4 alkyloxy-C 1-4 alkyl, (2) C 2-4 alkyloxy C 1-4 alkyl, (3) C 2-4 alkynyloxy — C 1-4 alkyl, (4) C 3-7 alkyloxy C 1-4 alkyl, (5) C 3-7 cycloalkyl (C 1-4 alkyloxy) mono C 1-4 alkyl, (6) phenoxy C 1-4 alkyl, (7) phenol C 1-4 alkyloxy — C 1-4 alkyl, (8 ) C 1-4 alkylthio-C 1-4 alkyl, (9) C 2-4 alkenylthio mono C 1-4 alkyl, (10) C 2-4 alkylthio mono C 1-4 alkyl, (11) C 3-7 cycloalkylthio mono C 1-4 alkyl, (12) C 3-7 cycloalkyl (C 1-4 alkylthi
- R 1E is C 1-6 alkyloxy, C 1-6 alkyloxy C 1-6 alkyloxy, or HO—C 1- 6 represents alkyloxy, and the 8-9 position represents a double bond.
- R 1 F represents a hydrogen atom, C 1-6 alkyl, phenyl — C 1-6 alkyl, C 2-6 alkanoyl, or ferro-C 2-6 alkanoyl,
- R 2F represents an oxygen atom or a halogen atom
- R 3F represents a hydrogen atom or hydroxy
- R 4aF and R 4bF each independently represent a hydrogen atom or C 1-4 alkyl;
- R 5F represents a phenyl group substituted with the following i) to: iv) groups: i) 1 to 3 (1) C 1-4 alkyloxy C 1-4 alkyl, (2) C 2-4 alkyloxy C 1-4 alkyl, (3) C 2-4 alkyloxy-C 1-4 alkyl, (4) C 3-7 alkyloxy C 1-4 alkyl, (5) C 3-7 cycloalkyl (C 1-4 alkyloxy) C 1-4 alkylenoquinole, (6) phenyloxy C 1-4 alkyl, (7) phenol C 1-4 alkyloxy — C 1-4 alkyl, (8) C 1-4 alkylthio C 1-4 alkyl, (9) C 2-4 alkylthio C 1-4 alkyl, (10) C 2-4 alkylthio mono C 1-4 alkyl, (11) C 3-7 cycloalkylthio mono C
- a G represents C 2-8 alkylene, C 2-8 alkenylene, C 1-4 alkylene 1-phenylene, or C 2-4 alkylene phenylene 1
- R 1G represents a hydrogen atom, C l-6 alkyl, Hue-Lu C 1-6 alkyl, C2-6 alkanoyl, Huenu Lu C 2-6 alkanoyl,
- R 2 G represents an oxygen atom or an atom atom
- R 3 G represents a hydrogen atom or a hydroxyl group
- R 4 G represents C 1-4 alkylene
- R 5 G represents a phenyl group substituted with the following i) to: iv) groups:
- a compound thereof, a salt thereof, an N-oxide or a solvate thereof, or These prodrugs or their cyclodextrin inclusion compounds are included.
- ⁇ represents a single bond or a double bond, ⁇ represents ⁇ a configuration, a configuration, or a mixture in any ratio thereof;
- DH represents one CO ⁇ R 1H or a tetrazolyl group.
- R 1H represents a hydrogen atom or a C 1-4 alkyl group
- G H represents a ring A H or a C 1-4 alkylene group
- ring A H represents
- R 2H represents a halogen atom, a C 1-4 alkyl group or a C 1-4 alkoxy group
- pH represents 0 or an integer of 1 to 4, and each R when pH is 2 or more. . 2H represents that may) be the same or different
- Y H represents a bond or a S-
- T H is an oxygen atom or a sulfur atom
- X H one CH 2 -, one O- or a Represents S—
- ring B H is an optionally substituted C 3-7 cycloalkyl group
- R 3H is (1) a halogen atom, (2) a C 1-4 alkyl group optionally substituted by 1 to 5 halogen atoms, and (3) 1 to 5 halogen atoms.
- C 1-4 alkoxy group which may be substituted
- C 1-4 alkyl group substituted with C 1-4 alkoxy group (5) phenyl group, or (6) oxygen atom, nitrogen atom
- (5) a phenol group or (6) heterocycle in R 3H is composed of 1 to 3 (a) halogen atoms, (b) C 1-4 alkynole groups, (c) C 1-4 alkoxy groups and And / or (d) may be substituted with a ditro group, qH represents 0 or an integer of 1 to 5, and when qH
- R 1J represents a hydroxyl group, C 1-4 alkoxy group, NHS0 2 — C 1-4 alkynole group or NHCO-phenenole group
- AJ ring represents a benzene ring or a thiophene ring
- R 2 J represents a hydrogen atom or a fluorine atom at the same time
- ⁇ represents a single bond or a double bond.
- R 2 J represents a fluorine atom
- the A J ring represents only the benzene ring.
- ⁇ ⁇ represents one CH 2 — or one ⁇ —
- ⁇ ⁇ represents one (CH 2 ) 3 —, chael, thiazolyl or phenyl group, but when ⁇ ⁇ is o, ⁇ ⁇ is a phenyl group,
- Q K represents a carboxyl group, a C 1-4 alkoxycarbonyl group or a tetrazolyl group
- 1 represents 1 ⁇ 1 or 8: 1: 11 ⁇ -1 ⁇ 81 " 21 ⁇
- V K represents a bond, 1 O—, 1 OCH 2 — or 1 CH 2 0—,
- Ar K may have 1 to 4 heteroatoms arbitrarily selected from an oxygen atom, a sulfur atom, or a nitrogen atom 5 to 8 membered partially saturated, fully saturated or all Arbitrarily selected from saturated cyclic group or oxygen atom, blue yellow atom, nitrogen atom May be selected from 1 to 4 heteroatoms Bicyclic ring formed by condensation of two 5- or 6-membered partially saturated, fully saturated or fully unsaturated cyclic groups Wherein a partially or fully saturated cyclic or bicyclic cyclic group has 1 or 2 oxo groups on the carbon or 1 or 2 oxo groups on the sulfur atom.
- a partially or fully saturated cyclic or bicyclic cyclic group has 1 or 2 oxo groups on the carbon or 1 or 2 oxo groups on the sulfur atom.
- a r 1 K and A r 2 K may each independently have 1 to 4 heteroatoms arbitrarily selected from an oxygen atom, a sulfur atom, or a nitrogen atom 5 to 8 Represents a partially saturated, fully saturated or fully unsaturated cyclic group, wherein the partially or fully saturated cyclic group is on one or two oxo or sulfur atoms on the carbon. May have 1 or 2 oxo groups,
- a r K is 3 on one ring, in the case of bicyclic, on one ring or on both rings, by a group selected from the following (1) to (29): May have a substituent on carbon or nitrogen; (1) hydroxy, (2) halogen atom, (3) carboxyl, (4) C 1-7 alkoxy, ( 5) C 1-4 alkoxy C 1-4 alkyl, (6) C 1-7 alkyl, (7) C 2-7 alkelle, (8) C 3-7 cycloalkyl, (9) C 3-7 cyclo Alkyl C 1-4 alkyl, (10) C 3-7 cycloalkyl C 1-4 alkanol, (11) Formyl, (12) ⁇ 1-8 ano decanol, (13) C 1-6 alkanoyl C 1-6 alkynole (14) C 1-4 alkanolumino, (15) C 1-4 alkoxycarbonylamino, (16) hydroxysulfol, (17) aminocarbolamino or C 1-4 alky
- the Ar 1K and Ar 2K may have a substituent on carbon or nitrogen by a group selected from the following (1) to (29), up to 3 substituents; (1) Hydroxy, (2) Halogen atom, (3) Carboxyl, (4) C1-7 alkoxy, (5) C1-4 alkoxy C1-4 alkyl, (6) C1-7 alkyl, (7) C 2-7 alkyl, (8) C 3-7 alkyl, (9) C 3-7 alkyl C 1-4 alkyl, (10) C 3-7 cycloalkyl C 1-4 alkanol, (11 ) Formyl, (12) C 1-8 al force noil, (13) C 1-6 al force noil C 1-6 alkyl, (14) C 1-4 alanolinoamino, (15) C 1-4 Alkoxycarbonylamino, (16) hydroxysulfonyl, (17) monoamino N-, di-N, N-, di-N, N, one or tree N, substituted with amino-powered polyamino or C1-4 alkyl.
- alkyl sulfonyl Le (29) mono- N- or di-one N, NC 1 to 4 alkylamino sulfinyl, alkyl in the definition of the a r 1K and a r 2K and Alkoxy substituents may be substituted with up to 3 fluorine atoms,
- R 2K represents chenyl, phenyl or chlorine, fluorine, phenyl, methoxy, trifluoromethoxy Or does not represent phenyl monosubstituted by C 1-4 alkyl
- R 2K is (I) C 5-7 cycloalkyl or (ii) phenyl, chael or furyl, each of which is (1) a haguchi atom or (2) one or more haguchi It does not represent a ring that may be mono- or di-substituted by a substituent selected from an atom or C 1-3 alkyl optionally substituted by C 1-4 alkoxy.
- the (L) WO 03/008377 pamphlet a compound represented by the following formula (IL) is described as having a EP 4 Agoesuto action.
- the definition of each group of the compound represented by the general formula (IL) is described in detail in WO 03/008377. Therefore, the EP 4 agonist of the present invention includes the general formula (IL)
- a L represents one CH 2 —CH 2 — or one CH ⁇ CH—
- B L represents a single bond, aryl or heteroaryl
- Z L is one of C (O) OR, L , — C (O) NR, L R ′′ L , — C (O) NSO 2 R, L , — PR, L (O) (OR, L ), one PO (OR, L ) 2 or tetrazonole 1-ynole (wherein R, L and R ′′ L each independently represents a hydrogen atom or C 1-6 alkyl).
- mL represents 1, 2, 3, 4, 5 or 6,
- R 1L , B L is aryl or heteroary
- R 3L , R 4L , R 5L And R 6 L at the same time do not represent a hydrogen atom, it represents alkyl, alkenyl, alkynyl, cycloalkylalkyl, heterocyclic alkyl, aryl, arylalkyl, heteroaryl, or B L is a single bond
- R 3L , R 4L , R 5 L and R 6 L simultaneously represent a hydrogen atom, they represent a heterocyclic alkyl, aryl, aryl alkyl, heteroaryl,
- R 2L represents a hydrogen atom, C 1-6 alkyl, C 1-6 alkuel or C 1-6 arnolequinole,
- R 3L , R 4L , R 5L and R 6L each independently represent a hydrogen atom or a C 1-6 alkyl, and R 3L and R 4L , R 5L and R 61 "or R 3L and R 5L are bonded atoms Together with C 3-7 alkyl ring.]
- R 4M each independently has a hydrogen atom, an optionally substituted alkyl, an optionally substituted carbocyclic aryl or a substituent! / Represents the ring to the aromatic aromatic,
- E M is a hydrogen atom, hydroxy, optionally substituted alkoxy or Represents an alkylthio which may have a substituent
- oM and pM each independently represent 0, 1 or 2, oM and! )
- the sum of M is at least 1,
- M M represents COX M , S0 2 X M (in the group, X M represents OR, M or NHR, M , and has R, H or a substituent) ) Represents an optionally substituted tetrazole, N0 2 , NHS0 2 R M or NHC (O) R M (wherein R M is H and has a substituent) Represents an optionally substituted alkyl).
- D M represents (CH 2 ) n " M (in the group, 11"] ⁇ represents an integer of 0 to 2)
- 'Q M is (CH 2 ) n "' M (in the group, n “, M represents 0 or 1.)
- each U M and V M has an alkyl which may have a substituent, alkenyl which may have a location substituent, alkynyl optionally having a substituent group, the substituent Represents an optionally substituted carbocyclic aryl or an optionally substituted aromatic heterocyclic ring.
- G M is CH 2
- n M is 3
- E M is the p M a hydrogen atom 2
- R 4M 2 there is oM hydrogen atom
- n M is 2, n
- M mosquitoes S0, V Excludes compounds where M is alkyl. Or a salt thereof, an N-oxide or a solvate thereof, a prodrug thereof, or a cyclodextrin inclusion compound thereof.
- R 1N each independently represents a hydrogen atom, an alkyl that may have a substituent, an alkiel that may have a substituent, an alkynyl that may have a substituent, Heteroalkyl which may have a group, Heteroalkyl which may have a substituent, Heteroalkyl which may have a substituent, which has a substituent
- G N has an oxo, a halogen atom and a substituent.
- Optionally substituted alkyl, optionally substituted alkoxy, hydroxy, alkyl Bokishireto represents optionally have a substituent alkyl carboxylate ester
- P N represents an integer of 0 to 4,
- U N and U 1N each independently represent a hydrogen atom, hydroxy or optionally substituted alkyl
- a N represents O, S, (CR 2N R 3N ) a ' N (wherein q and N are integers from 1 to 6) To express. ),
- B N represents (CR 2N R 3N ) nN or a single bond
- a N and B N together form an optionally substituted 1,2-vinylene or ethynylene
- V N represents (CR 2N R 3N ) mN , a divalent aryl which may have a substituent, or a divalent heteroaryl which may have a substituent,
- L N represents C (O) Z N
- Z N is hydroxy, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkyl, or optionally substituted.
- nN represents an integer of 0 to 3
- n 1 to 6
- R 4N and R 5N each independently represent a hydrogen atom, an optionally substituted alkyl, an optionally substituted cycloalkyl, or an optionally substituted heterocycloalkyl.
- x p represents a single bond, an oxygen atom or a sulfur atom
- Y p 0 or 1 OH
- R 1P is hydroxy, CN, (CH 2 ) pP C0 2 R 6P , (CH 2 ) nP S0 3 R 6 p , one CF 2 SO 2 NH 2 , one S0 2 NH 2 , one CHNHS0 2 R 2P , — S0 2 NH COR 6P , -PO (OH) 2 , CONHPO 2 R 6P , CONHR 8P , C 1 to 4 anorecoxy, one (CH 2 ) nP NR 6P R 7P , hydroxymethyl ketone or one (CH 2 ) nP heterocycle the stands, the heterocycle may contain an acidic hydrogen atom, which is not to have been or substituted one to three substituted by R aP, R 2P are hydrogen atom, C 6 to 10 Ariru Or C 1-4 alkyl, R 3 p and R 4 P each independently represent a hydrogen atom, a halogen atom or C 1-6 alkyl,
- R 5P is, (CH 2) mP C 6 ⁇ : L 0 Ariru, (CH 2) mP C 5 ⁇ : L 0 Heteroa reel, (CH 2) mP C 3 ⁇ : L 0 heterocycloalkyl or (CH 2) mP C represents 3 to 10 cycloalkyl, the alkyl ring, the heavy alkyl ring , Aryl or heteroaryl is one to three substituted or unsubstituted by R ap
- R 6P and R 7P represent a hydrogen atom or C 1-4 alkyl
- R 8P represents a hydrogen atom or sulfonyl
- Z p is (C (R bP ) 2 ) nP ,
- Each R bP independently represents a hydrogen atom, a halogen atom, C 1-6 alkyl or C 3-6 alkyl;
- R aP represents C 1-6 alkoxy, C 1-6 alkyl, CF 3 , utro, amino, .ciano, C 1-6 alkylamino or a halogen atom,
- p P 1 to 3
- n P 0-4
- mP 0-8.
- Q Q is CH 2 and X Q is one NR aQ — (R aQ represents a hydrogen atom, a halogen atom, C 1-6 alkyl, C 1-6 acyl), one O—, 1 S—, 1 SO—, 1 S0 2 — or a single bond, provided that when X Q is a single bond, Q Q is an oxygen atom,
- Z Q is CH 2 OH, 1 C (O) OR, Q , 1 C (O) NR, Q R, Q , 1 C (O) N S0 2 R, Q , 1 P (C 1-6 alkyl) ) (O) (OR, Q ), 1 PO (OR, Q ) 2 or tetrazole 1-5yl (wherein R ′ Q and R ′′ Q are each independently a hydrogen atom or C 1-6 alkyl Represents)
- R 1Q one in (CH 2) pQ R 7Q or a (CH 2) qQ OR 8Q
- group, R 7Q and R 8 Q are each independently, C. 1 to 6 alkyl, halo C. 1 to 6 alkyl, C 3 to 6 cycloalkyl, heterocycle, aryl or heteroaryl, p Q and each independently represent 0, 1, 2, 3, 4 or 5.
- R 2Q represents a hydrogen atom, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkini / re,
- R 3Q , R 4Q , R 5Q and R 6Q each independently represent a hydrogen atom or C 1-6 alkyl.
- T R represents (1) an oxygen atom, or (2) a sulfur atom
- X R represents (1) —CH 2 — group, (2) —O— group, or (3) —S— group,
- a R represents A 1R or A 2R ,
- a 1R is (1) a linear C 2-8 alkylene group optionally substituted with 1-2 C 1-4 alkyl groups, (2) 1-2.
- a 2R represents one G 1R — G 2R — G 3R — group
- G 1R is (1) a linear C 1-4 alkylene group optionally substituted with 1-2 C 1-4 alkyl groups, and (2) 1-2 C 1-4 alkyl groups. Even if it is replaced A straight-chain C 2-4 alkenelene group, or (3) a straight-chain C 2-4 alkanolene group optionally substituted with 1-2 C 1-4 alkyl groups,
- G 2R is (1) —Y R —group, (2) —ring 1 R —group, (3) —Y R —ring 1 R —group, (4) part 1 R 1 Y R —group, or ( 5) — Y R — C 1-4 alkylene moiety 1 R — represents a group, Y R represents (1) —S— group, (2) —SO— group, (3) —S0 2 — group, (4 ) — O— group, also! (5) — NR 1R — represents group,
- R 1R represents (1) a hydrogen atom, (2) a C 1-10 alkyl group, or (3) a C 2-10 acyl group.
- G 3R consists of (1) a single bond, (2) a linear C 1-4 alkylene group that may be substituted with 1-2 C 1-4 alkyl groups, and (3) 1-2 A linear C 2-4 alkylene group optionally substituted with a 01-4 alkyl group, or (4) a linear chain optionally substituted with 1-2 C 1-4 alkyl groups
- C 2-4 represents an alkylene group
- D R represents D 1R or D 2R ,
- D 1R represents (1) one COOH group, (2) —COOR 2R group, (3) tetrazol-5-yl group, or (4) —CONR 3R S0 2 R 4R group,
- R 2R represents (1) a C 1-10 alkyl group, (2) a phenol group, (3) a C 1-10 alkyl group substituted with a fuel group, or (4) a biphenyl group,
- R 3R represents (1) a hydrogen atom, or (2) a C 1-10 alkyl group
- R 4R represents (1) C 1-: L 0 alkyl group, or (2) a phenyl group,
- D 2R is (1) —CH 2 OH group, (2) —CH 2 OR 5R group, (3) hydroxyl group, (4) —OR 5R group, (5) formyl group, (6) —CONR 6R R 7R Group, (7) —CONR 6R S0 2 R 8R group, (8) — CO— (NH—one amino acid residue CO) mR — OH group, (9) — O— (CO—amino acid residue one NH ) mR — H group, (10) — COOR 9R group, (11) — OCO— R 10R group, (12) — COO— Z 1R — Z 2R — Z 3R group, or (13)
- R 5R represents a C 1-10 alkyl group
- R 6R and R 7R each independently represent (1) a hydrogen atom, or (2) a C 1-10 alkyl group,
- R 8R represents a C 1-10 alkyl group substituted with a fuel group
- R 9R is substituted with a biphenyl group which may be substituted with 1 to 3 substituents selected from (1) a C 1-10 alkyl group, an O 1-10 alkoxy group, and a halogen atom.
- C 1-: L 0 ananolyl group, or (2) a biphenyl group substituted with 1 to 3 substituents selected from a C 1-10 alkyl group, a C 1-10 alkoxy group, and a halogen atom Represents
- R 10R represents (1) a phenyl group, or (2) a C 1 to: L 0 alkyl group,
- mR 1 or 2
- Z 1R is (1) a C 1-15 alkylene group, (2) a C 2-15 alkenylene group, or
- (3) represents a C 2-15 anolylene group
- Z 2R consists of (1) one CO— group, (2) — OCO— group, (3) — CO 2 O— group, (4) — CONR z 1R — group, (5) — NR z2R CO— group, ( 6) — O— group, (7) — S— group, (8) _S0 2 _ group, (9) one SO 2 — NR Z2R — group, (10) — NR Z2R S0 2 — group, (11) — NR Z3R — group, (12) one NR Z4R CONR z5R — group, (13) — NR Z6R COO— group, (14) one OCONR z 7R — group, or (15) — OCOO— group,
- Z 3R includes (1) a hydrogen atom, (2) a C 1-15 alkyl group, (3) a C 2-15 alkyl group,
- Ring Z R may be (1) partially or fully saturated C 3-15 monocyclic, bicyclic or tricyclic carbocyclic aryl, or (2) oxygen, nitrogen, and sulfur atoms Including 1 to 4 heteroatoms selected from the child, partially or fully saturated Represents a 3-15 membered monocyclic, bicyclic or tricyclic heteroaryl,
- R Z 1 R , R Z 2R , R Z 3 R , RZ 4 R , R Z 5 R , R Z 6 R , R Z 7 R, and RZ 8 R are each independently a hydrogen atom or a C 1-15 alkyl group. Represent,
- R Z1R and Z 3R groups together with the nitrogen atom to which they are attached may represent a 5- to 7-membered monocyclic saturated heterocycle, the heterocycle further comprising an oxygen atom, a nitrogen atom A monocyclic saturated heterocycle represented by the ring Z R , and the nitrogen atom to which R Z1R and Z 3R are bonded. May be substituted with 1 to 3 groups selected from the following (1) to (4);
- C 1-15 alkyl group (2) C 2-15 alkenyl group, (3) C 2-15 alkyl group, (4) C 1-10 alkoxy group, C 1-10 alkylthio group, or C 1-10 alkyl mono NR Z9R — a C 1-10 alkyl group substituted with a group;
- R Z9R represents a hydrogen atom, or a C 1-10 alkyl group;
- E R represents E 1R or E 2R ,
- R 11R is (1) a C 1-10 alkyl group, (2) C 1: a L 0 alkylthio group, (3) a C 1-10 alkyl group substituted with a C 3-8 cycloalkyl group, (4) A C 1-10 alkyl group substituted with ring 2 R , or (5) —W 1R _W 2R — a C 1-10 alkyl group substituted with ring 2 1 ,
- W 1R consists of (1) ⁇ 0—group, (2) —S—group, (3) —SO—group, (4) one S0 2 —group, (5) —N Rii-1R—group, (6 ) A carbur group, (7) _NRn— 1R S0 2 — group, (8) a carboel amino group, or (9) an amino carboel group,
- R 11 — 111 represents (1) a hydrogen atom, (2) C 1-: L 0 alkyl group, or (3) C 2-; L 0 acyl group,
- W 2R is (1) a single bond, or (2) a C 1-4 alkyl group, a halogen atom, or water Represents a C 1-8 alkyl group optionally substituted with an acid group,
- E 2R represents (1) U 1R — U 2R — U 3R group, or (2) ring 4 R group,
- U 1R is: (1) C 1-4 alkylene group, (2) C 2-4 alkenylene group, (3) C 2-4 alkylene group, (4) —ring 3 R — group, (5) C 1— 4 represents an alkylene group part 3 R — group, (6) C 2-4 alkenylene group part 3 R — group, or (7) C 2-4 alkynylene group part 3 R — group,
- U 2R consists of (1) single bond, (2) —CH 2 — group, (3) —CHOH— group, (4) — O— group, (5) —S— group, (6) —SO— group. , (7) — S0 2 — group, (8) — NR 12R — group, (9) Carbonyl group, (10) —NR 12R SO 2 — group, (11) Carbonylamino group, or (12) Represents an amino force group,
- R 12R represents (1) a hydrogen atom, (2) a C 1-: L 0 alkyl group, or (3) a C 2-: L 0 alkyl group,
- U 3R may be substituted with 1 to 3 substituents selected from (1) C 1-10 alkyl group, halogen atom, hydroxyl group, alkoxy group, alkylthio group, and NR 13R R 14R group C 1 to 8 alkyl groups, (2) substituted with 1 to 3 substituents selected from the group consisting of C 1-10 alkyl groups, neurogen atoms, hydroxyl groups, alkoxy groups, alkylthio groups, and 1 1313 ⁇ 4 1 1411 groups good C.
- 2 to 8 alkenyl group which may, (3) C 1 to 10 alkyl group, a halogen atom, a hydroxyl group, an alkoxy group, Al Kiruchio group, and - with 1 to 3 substituents selected from NR 13R R 14R group An optionally substituted C 2-8 alkynyl group, (4) a C 1-8 alkyl group substituted with a ring 4 R group, or (5) a ring 4 R group,
- Oyopi 11 1411 each independently, represent (1) hydrogen atom or (2) C 1 to 10 alkyl group,
- Ring 1 R , Ring 2 R , Ring 3 R , or Ring 4 R may be substituted with 1 to 5 R R ,
- R R is (1) C 1-; L 0 alkyl group, (2) C 2-: L 0 alkyl group, (3) C2-1 0 alkynyl group, (4) C 1-10 alkoxy group, (5) C 1-10 alkylthio group, (6) halogen atom, (7) hydroxyl group, (8) -tro group, (9) —NR 15R R 16R A group, (10) a C 1-10 alkanol group substituted with a C 1-10 alkoxy group, (11) a C 1-10 alkynole group substituted with 1 to 3 halogen atoms, (12) 1-3 C 1-substituted with 1 halogen atom: C 1-substituted with L 0 alkoxy group: L 0 alkyl group, (13) — C 1-substituted with NR 15R R 16R group; L 0 alkyl group , (14) the ring 5 R group, (15) - O-ring 5 R group, (16) the ring 5 R C 1 to 10 al
- R 15R , R 16R , and R 17R each independently represent (1) a hydrogen atom, or (2) a C 1-10 alkyl group,
- Ring 5 R may be substituted with 1 to 3 substituents selected from the following (1) to (9);
- E R represents E 2R
- E 2R is U 1R - U 2R - when represents a U 3R group
- U 1R represents a C2 alkylene group or a C 2 alkenylene group
- U 3R represents a C 1-8 alkynole group substituted by at least one hydroxyl group
- U 1R — U 2R does not represent a C 2 alkylene group or a C 2 alkenylene group
- T R represents an oxygen atom
- X R gar CH 2 - represents a group
- D R represents D 1R
- D 1R represents a COOH group
- a R represents A 1R
- a 1R is a linear C 2-8 represents an alkylene group-
- E R represents E 2R , E 2 SU 1R — U 2R — U 3R , 11 11 .
- U 2 R does not represent a single bond, _CH 2 — group, one NR 12R — group, or a carbonyl group,
- T R represents an oxygen atom
- X R is one CH 2 - represents a group
- D R represents D 1R
- D 1R represents a COOH group
- a R represents A 2R
- G 1R is C 1 represents a ⁇ 4 alkylene group
- G 2R guard O- group or _NR 1R - represents a group
- G 3R represents a single bond or C 1 to 4 alkylene group
- E R represents E 2R
- E 2R is U 1R — U 2R — U 3R , when U 1R represents a C 1-4 alkylene group and U 3R represents a C 1-8 alkyl group
- U 2R is a single bond, one CH 2 — group, one NR 12R — does not represent a group or carboel group,
- T R represents an oxygen atom
- X R represents one CH 2 — group
- D R represents D 1R
- E R represents E 2R
- U 3R 11 111 represents a ⁇ 2 alkylene group or a C 2 alkylene group
- U 2R represents a CO— group
- a R does not represent A 1R
- R s is CO 2 R 4S , CONR 4S 2 , CH 2 OR 4S , CONR 4S S0 2
- R 4S represents a hydrogen atom, phenyl, C 1-6 alkyl
- R 1S and R 2S are each independently a hydrogen atom, hydroxy, C 1
- Kyroxy represents C1-6 acyloxy
- R 3 s represents a hydrogen atom, C 1-6 alkyl, C 1-6 acyl,
- Y s represents a single bond, or one CH 2 —, one O—, one S—, one N—
- Z s is a hetero atom selected from the group consisting of C 3-10 alkyl, C 3-10 cycloanolenole, 6-10 membered aromatic carbocycle, nitrogen atom, oxygen atom, and sulfur atom. Including a 4- to 10-membered aromatic heterocycle. ]
- Q T is (CH 2 ) mT , (CH 2 ) mT — C6 ⁇ ; L 0 aryl, (CH 2 ) mT — C 5-10 heterocycle, (CH 2 ) mT — C 3-10 Heterocyclic alkyl, (CH 2 ) mT — C 3-8 cycloalkyl, represents methylene substituted with two halogens, wherein the cycloalkyl, heterocyclic alkyl, aryl, heterocycle has 1 to 3 R a ⁇ May be replaced with
- ⁇ ⁇ and ⁇ ⁇ independently represent a methylene group, an oxygen atom, and a nitrogen atom and a sulfur atom substituted by R 9T , respectively, provided that ⁇ ⁇ ⁇ ⁇ and ⁇ ⁇ ⁇ are simultaneously substituted by an oxygen atom and R 9 ⁇ .
- U T represents a hydrogen atom, C 1-3 alkyl, and present when W T represents an oxo group. Not exist,
- R 1T is, - (CH 2) pT - heat Dorokishi, - (CH 2) pT - Shiano one (CH 2) pT - CO 2 R 10T, one (CH 2) nT - S0 3 R 6T, one (CH 2 ) pT -CF 2 SO z NH 2 ,-(CH 2 ) pT -S0 2 NH 2 --(CH 2 ) pT -C ONH SO 2 R 2T , one (CH 2 ) pT -SO 2 NHCOR 2T , one (CH 2 ) pT — PO (OH) 2 , (CH 2 ) pT —CONHP0 2 R 6T , one (CH 2 ) pT —CONHR 8T , one (CH 2 ) pT -C 1-4 alkoxy,-(CH 2 ) pT —cycloalkyl, — (CH 2 ) pT —hydroxymethylketone, one (CH 2
- R 2 ? Is independently C 1 to: L 0 alkyl, (CH 2 ) mT — C 6 to 10 aryl, (CH 2 ) mT — C 5 to: L 0 heterocycle, (CH 2 ) mT — C 3-10 heteroalkyl, (CH 2 ) mT — C 3-8 cycloalkyl, O— C 1-10 alkyl, O— C6—; L 0 aryl, O— C 3-10 cyclo Norequinole, Q—C3 ⁇ ; L 0 represents a heterocycle alkyl, provided that R 2T is O—C 1-10 alkyl, O—C6-10 aryl, O—C 3—: L 0 cycloalkyl, O — C 3-10 heterocycle When alkyl represents R 3 ⁇ and R 4 ⁇ do not represent halogen, the alkyl, cycloalkyl, heterocycle alkyl, aryl, heterocycle is 1 to 3 1 May be replaced,
- R 3T and R 4T each independently represent a hydrogen atom, halogen, C 1-6 alkyl, and R 3T and R 4T are taken together as an oxygen atom, a sulfur atom, SO, SO 2 and R 9T 1 to 2 heteroatoms selected from substituted nitrogen atoms may be included, may form a 3 to 7 membered carbocycle,
- R 6T and R 7T each independently represent a hydrogen atom, C 1-4 alkyl
- R 8T represents a hydrogen atom, an acyl, a sulfonyl
- R 9T represents a hydrogen atom, C 1-6 alkyl, and the alkyl is 1 to 3 halogens, cyan, hydroxy,. 1-6A ⁇ Coxi, C1-6Asinoleoxy, optionally substituted with an amino group,
- R 10T is a hydrogen atom, C 1-10 alkyl, C 3-10 cycloalkyl, (CH 2 ) pT —C 6—: L 0 aryl, (CH 2 ) pT — C 5-10 heterocycle, CR 6T R 7T OC (O) O—C 3—: L 0 cycloalkyl, CR 6T R 7T OC (O) O—C 1-10 represents alkyl,
- R bT represents a hydrogen atom, C 1-6 alkyl, halogen
- R aT represents C 1-6 alkoxy, C 1-6 alkyl, CF 3 , nitro, amino, cyano, C 1-6 alkylamino, halogen, R aT further represents aryl, heterocycle, S— C 1-6 alkyl, S—C 6-10 aryl, S—C 5 —; L 0 heterocycle, CO 2 R 6T , O—C 6-10 aryl, O—C 5—; L 0 heterocycle, CH 2 0 — C 1-6 alkyl, CH 2 S— C 1-6 alkyl, CH 2 O
- pT 0-3
- ⁇ 0-4
- mT 0-8.
- U u represents a hydrogen atom, C 1-3 alkyl, and when W u represents an oxo group, it does not exist,
- w u represents a hydroxyl group or an oxo group, provided that u u does not exist when w u represents an oxo group,
- R 1U represents (CH 2 ) pU —hydroxy, (CH 2 ) pU _CO 2 R 10U , (CH 2 ) nU heterocycle, and the heterocycle may be substituted with 1 to 3 R aU Well, it may contain acidic hydroxy groups,
- R 2U is independently C 1-; L 0 alkyl, (CH 2 ) mU _C 6-10 aryl, (CH 2 ) mU — C 5-10 heterocycle, (CH 2 ) mU — C3—: L 0 Heteroalkyl, (CH 2 ) mU — represents C 3-8 cycloalkyl, wherein the alkyl, cycloalkyl, heteroalkyl, aryl, heterocycle may be substituted with ⁇ to ⁇
- R 3U and R 4U each independently represent a hydrogen atom, a halogen, and 1 to 6 aralkyl
- R 6U represents a hydrogen atom, C 1-4 alkyl
- R 1 ou represents a hydrogen atom, C 1 to: L 0 alkyl, C 3 to 10 cycloalkyl, (CH 2 ) pU — C 6 to 10 aryl, (CH 2 ) pU — C 5 to 10 heterocycle, R aU is C 1-6 alkoxy, C 1-6 alkyl, CF 3 , nitro, amino, Ciano, C 1-6 alkylamino, halogen, R aU further represents aryl, heterocycle, S—C 1-6 alkyl, S—C 6-10 aryl, S—C 5 —; L 0 heterocycle, O — C6-10 aryl, O— C5-10 heterocycle, C0 2 R 6U , CH 2 0— C 1-6 alkyl, CH 2 S— C 1-6 alkyl, CH 2 0— aryl, CH 2 S— Represents the reel
- ⁇ Represents a double bond or a single bond
- pU represents 0-3
- nU 0-4
- mU 0-8.
- nW 0-4
- R aW represents a hydrogen atom or alkyl.
- Z w represents 1 CH 2 OH, 1 CHO, 1 tetrazonore 1-5-isle, 1 COOR bW (where R bW represents a hydrogen atom or alkyl),
- Particularly preferred compounds include: ( ⁇ 3— [((1 R, 2 S, 3R) -3-Hydroxy 1- 2- ⁇ (IE, 3 S) 1 3-Hydroxy-1 4 1 [3-- [Fu-Nole] Puta 1-enenore ⁇ — 5-Oxocyclopentinole) Sulfur] Propyl ⁇ Sunolephanyl) Acetic acid; 4— ⁇ [2— ((1R, 2R, 3 R) —3—Hydroxy 1 2— ⁇ (1 E, 3 S) —3—Hydroxy 1 4-1 [3- (Methoxymethyl) fuel] pt 1 1-el ⁇ —5--oxocyclopentyl) ethyl] sulfanyl ⁇ ptanoic acid; 1 ((1R, 2R , 3R) — 3-Hydroxy 1- 2 ⁇ (1E, 3 S) 1 3-Hydroxy 1 4 1 [3- (Methoxy
- an alkyl group, an alkyl group, an alkyl group, an alkyl group, an alkyloxy group, an alkoxy group, an alkenyloxy group, an alkynyloxy group, Alkylthio group, alkylsulfinyl group, alkylsulfol group, alkylene group, alkenylene group, arolequinylene group, acyl group and asiloxy group include straight-chain and branched-chain ones.
- the compound represented by the general formula (I) is converted into a salt by a known method.
- the salt is preferably non-toxic and water-soluble.
- Examples of the salt of the compound of the present invention include salts of alkali metals (potassium, sodium, lithium, etc.), salts of alkaline earth metals (calcium, magnesium, etc.), ammonium salts (tetramethyl ammonium salt, tetraptyl ammonium salt, etc.) ), Organic amines (triethylamine, methylamine, dimethylamine, cyclamine pentinoreamine, benzylamine, phenethylamine, piperidine, monoethanolanolamine, jetanolamine, tris (hydroxymethyl) methylamine, lysine, arginine, N-methyl- D-Dalkamine, etc.), acid adduct salts (inorganic acid salts (hydrochloride, hydrobromide, hydrofluoride, sulfate, phosphate,
- N-oxide represents a compound in which the nitrogen atom of the compound represented by the general formula (I) is oxidized.
- the compound represented by the general formula (I), a salt thereof or an N-oxide compound of the present invention or a salt thereof can be converted into a solvate by a known method.
- Solvates are preferably non-toxic and water-soluble.
- examples of the solvate of the compound of the present invention include solvates such as water and alcohol solvents (for example, methanol, ethanol and the like).
- the compound of the present invention represented by the general formula (I), a salt thereof, an N-oxide, a solvate thereof or a prodrug thereof is ⁇ -,; 3- or y- Conversion to cyclodextrin inclusion compounds using the method described in JP-B-50-3362, 52-31404, or 61-52146 using clodextrin or a mixture of these Can do.
- cyclodextrin inclusion compound stability is increased and water solubility is increased, which is convenient for use as a drug.
- the prodrug of the compound of the present invention refers to a compound that is converted into a compound represented by the general formula (I) by a reaction with an enzyme, gastric acid or the like in a living body.
- the prodrug of the compound of the present invention for example, when the compound of the present invention has an amino group, the compound in which the amino group is acylated, alkylated or phosphorylated (for example, the amino group of the compound of the present invention is eicosanolated, arael , Pentylaminocarbonylation, (5-Methyl-2-oxo-1, 3-Dioxolene 41- 1) Methoxycarbonyl, tetrahydrofuranylation, Pyrrolidylmethylation, Bivalyloxymethylation, Acetoxymethyl , Tert-butylated compounds, etc.): When the compound of the present invention has a hydroxyl group, the hydroxyl group is acylated, alkylated, phosphorylated
- the prodrug of the compound of the present invention may be either a hydrate or non-hydrate.
- the prodrugs of the compounds of the present invention can be converted to the compounds of the present invention under physiological conditions as described in Yodogawa Shoten 1990, “Development of Pharmaceuticals”, Chapter 7 “Molecular Design”, 163-3198. It may change.
- the present invention compounds isotopes e.g., 3 H, 1 4 C, 3 5 S, 1 2 5 I
- the compound of the present invention represented by the general formula (I), its salt, its N-oxide, its solvate or their prodrug, or their cyclodextrin inclusion compound (hereinafter collectively referred to as the present compound) ) Is excellent in solubility, absorption and metabolic stability, has long-lasting pharmacological activity (EP 4 agonist activity), and is weakly inhibited by drug-metabolizing enzymes. It is a compound with low toxicity such as action. These properties are the most important physical, chemical, and pharmaceutical properties required for development as pharmaceuticals. The compounds of the present invention satisfy these conditions and have the potential to become very excellent pharmaceuticals. Has [The Merck Manual of Diagnosis and Therapy (17th Ed.), Merck & Co. See also]
- the compound of the present invention may be produced by a known method, for example, WO 03/009872 International Publication No. 00/003980 Pamphlet, European Patent Publication No. 855389, European Patent Publication No. 985663, International Publication No. 00/015608 Pamphlet, International Publication No.
- EP 4 agonists are useful as preventive and Z or therapeutic agents for lower urinary tract diseases.
- it is useful as a preventive and Z or therapeutic agent for cystitis opso Z or urethritis.
- EP 4 agonists are useful for the prevention and / or treatment of lower urinary tract diseases, and are therefore symptoms of lower urinary tract diseases (1) frequent urination, (2) urgency, (3) genitals Opi Z or lower urinary tract pain (eg, bladder pain, urethral pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain, etc.) and Z or (4) Genital and Z or lower It is useful for improving urinary tract discomfort.
- genitals Opi Z or lower urinary tract pain eg, bladder pain, urethral pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain, etc.
- EP 4 agonists are useful because they improve bladder capacity and Z or bladder compliance, and protect and promote Z or regeneration of bladder mucosa and Z or bladder epithelial cells.
- EP 4 agonists which are preventive and / or therapeutic agents for lower urinary tract diseases of the present invention are: 1) complementation and / or enhancement of therapeutic effects of lower urinary tract diseases, 2) of EP 4 agonists of the present invention To improve kinetics / absorption, reduce dose, and Z or 3) To reduce side effects of the EP 4 agonist of the present invention, it may be administered in combination with other drugs. .
- the combination agent of EP 4 agonist of the present invention and other drugs may be administered in the form of a combination preparation in which both components are combined in one preparation, or may be in the form of administration as separate preparations.
- simultaneous administration and administration by time difference are included.
- administration by the time difference, the E p 4 Agonisuto of the present invention is administered first, administration may be administered after the other drug is administered other drugs previously, after the EP 4 Agonisuto of the present invention
- the administration method may be the same or different.
- the other drug may be a low molecular weight compound, and is a high molecular protein, polypeptide, polynucleotide (DNA, RNA, gene), antisense, decoy, antibody, or vaccine Etc.
- the dosage of other drugs can be appropriately selected based on the clinically used dose.
- the blending ratio of the EP 4 agonist of the present invention and other drugs can be appropriately selected depending on the age, body weight, administration method, administration time, etc. of the administration subject. For example, 0.001 to 100 mass parts of other drugs may be used per 1 mass part of EP 4 agonist of the present invention. Two or more other drugs may be administered in combination at an appropriate ratio.
- drugs that complement and Z or enhance the therapeutic effect of lower urinary tract diseases of the present invention include not only those that have been found so far, but also those that will be found in the future based on the mechanism described below. included.
- -Other drugs include, for example, heparin preparations, dimethyl sulfoxide preparations, hyaluronic acid preparations, rejuferatoxin preparations, botulinum toxin preparations, sodium bentonate polysulfate preparations, antidepressants, antibiotics, analgesics
- anti Anticonvulsants, antihistamines, antiallergic drugs, other urinary tract diseases drugs eg anticholinergic drugs, agonists, ⁇ ⁇ antagonists, GABA agonists, antidiuretics, antimale hormones, luteinizing hormones, antagonists, ] 3 3 agonists, ⁇ 2 X antagonists, forceful channel opener, LPA, cap.
- Saicin (resiniferatoxin), muscarinic (Ml, M3) antagonist, 5—HT reuptake inhibitor, 5—HT 1A antagonists, ACh Anta Goyusuto, C a channel antagonism varnish DOO, E Pi Antagoesuto, EP 3 Ann Tagonisuto.), and the like.
- antidepressants examples include tricyclic antidepressants (eg, imibramin hydrochloride, desipramine hydrochloride, clomipramine hydrochloride, trimipramine maleate, amitriptyline hydrochloride, no / retriptyline hydrochloride, fepramine hydrochloride, amoxapine, doslevine hydrochloride, etc.) And tetracyclic antidepressants (for example, maprotiline, mianserin, etc.).
- tricyclic antidepressants eg, imibramin hydrochloride, desipramine hydrochloride, clomipramine hydrochloride, trimipramine maleate, amitriptyline hydrochloride, no / retriptyline hydrochloride, fepramine hydrochloride, amoxapine, doslevine hydrochloride, etc.
- tetracyclic antidepressants for example, maprotiline,
- Antibiotics include, for example, cefuroxime sodium, meropenem trihydrate, netilmycin sulfate, sisomycin, ceftibutene, PA—1806, IB—367, topramycin, PA-1420, doxorubicin, astromycin sulfate And cefetamethotopivoxil hydrochloride.
- inhaled antibiotics include PA-1806, IB-367, tobramycin, PA-1420, doxorubicin, astromycin sulfate, ceftametopivoxil hydrochloride, and the like.
- Anticonvulsants include, for example, canolebamazepine, phenytoin, ethotoin, mehobarbital, metalbital, primidone, trimethadione, acetylsulfate, ethosuximide, sodium valproate, acetazolide, clonazepam, zepamide, etc.
- Analgesic ⁇ Anti-inflammatory drugs include ergotamine preparations (eg, dihydroergotamine mesylate, ergotamine tartrate, etc.), obioid receptor agonists (For example, morphine sulfate, morphine hydrochloride, pethidine hydrochloride, fentanyl, pentazocine, buprenorphine hydrochloride, etc.), steroid drugs, non-steroidoid anti-inflammatory drugs, and the like.
- ergotamine preparations eg, dihydroergotamine mesylate, ergotamine tartrate, etc.
- obioid receptor agonists For example, morphine sulfate, morphine hydrochloride, pethidine hydrochloride, fentanyl, pentazocine, buprenorphine hydrochloride, etc.
- steroid drugs non-steroidoid anti-inflammatory drugs, and the like.
- topical steroid drugs include clobetasol propionate, diflorazone acetate, fluoconide, mometasone furanate, betamethasone dipropionate, betamethasone butyrate propionate, betamethasone valerate, difluprednate, pudesud, Yoshi Diflucortron herbate, amsinonide, hanoresinoed, dexamethasone, dexamethasone propionate, dexamethasone valerate, dexamethasone acetate, hydrocortisone acetate butyrocortisone butyrate, hydrocortisone butyrate propionate, deprodonone niproate benzoate , Methasone propionate, triamcinolone acetate, flumethasone pivalate, propionate Examples include clomethasone, clobetasone butyrate, prednisone, peclomethasone propionat
- Inhalation steroids include, for example, beclomethasone propionate, fluchizone propionate, pudesud, flusolide, triamcinomouth, ST-1 2 6 P, ciclesud, dexamethasone paromithionate, mometa Zonfuran carbonate, plasterone sulfonate, deflazacoat, methinorepredusolone sulpheptaneate, methinorepred-zoganatotrimusuccinate and the like.
- Non-steroidal anti-inflammatory drugs include, , Crinolyl, Fenbufen, Napumetone, Progourmetacin, Indomethacin, Farnesyl, Acemetacin, Progouritacin, maleate, Amphenacnatrum, Mohuezolak, Etodolac, Ibuprofen, Ibuprofen Picconol, Naproxen, Flurbi Profen, Flurbip Oral Fen Axetinore, Ketoprofen, Fenoprofen Power / Rethym, Thiaprofen, Oxap Rosin, Planoprofen, Loxoprofen sodium, Aluminoprofen, Zaltoprofen, Mefenamic acid, Mejuenamate aluminum, Tolfenamic acid, Fractafeyun, Keto-Fe-butazone, Oxifeptazone, Piroxicam, Tenoxicam, Napagel Epilizole, thiaramide
- Antihistamines include, for example, ketotifen fumarate, mequitazine, azelastine hydrochloride, oxatomide, terfenadine, emedastine fumarate, epinastine hydrochloride, istemizole, ebastine, cetirizine hydrochloride, bepotastine, fexofenadine, oral lutatadine Latazine, olopatadine hydrochloride, T AK— 4 2 7, ZCR— 2 0 60, NIP— 5 3 0, mometasone mouthate, mizolastine, BP— 2 9 4, Andlast, auranobuin, Ataripastin etc. are mentioned.
- Antiallergic drugs include, for example, allergen extract, amlexanox, azelastine hydrochloride, bepotastine besylate, cetirizine hydrochloride, ebastine, emedastine fumarate, epinastine hydrochloride, fuexofenazine hydrochloride, ibudilast, ketotifen fumanoleate, oral latazine, Monte ⁇ / castnatrium, olopatadine hydrochloride, oxatomide, ozadarel hydrochloride, pemirolast potassium, pranlukast hydrate, ramatroban, levirinast, seratrodast, cromoglyc.sodium acid, suplatast tosilate, tazanolast, tranilast It is done.
- Anticholinergic agents include, for example, oxybutynin hydrochloride, betanechol chloride, propiverine hydrochloride, propantheline bromide, methylbenactidimate bromide, butylscopolamine bromide, tolterodine tartrate, trospium chloride, Z-338, K-112166-04, ONO-8025, Darifenacin, YM-905 and so on.
- Examples of the Mus force phosphorus antagonist include YM905, ONO-8025 and the like.
- Jagoest examples include midodrine hydrochloride and the like.
- alpha iota Antagoyusuto for example, hydrochloric terazosin, bunazosin hydrochloride, Urapijiru, tamsulosin hydrochloride, doxazosin mesylate, prazosin hydrochloride, indoramin, Nafutobijiru, hydrochloric alfuzosin, AI ⁇ - 8 5 0 7 L, and the like.
- GA B Agoest examples include butterfly fen and midazolam as well as most minor tranquilizers.
- diuretic examples include mannitol, furosemide, acetazolamide, dichlorfenamide, metazolamide, trichloromethiazide, mefluside, spironolataton, and aminobuline.
- EPi antagonists are described, for example, in WO98 / 27053. And the compounds described in EP878465, or the compounds described in WO02 / 72564.
- EP 3 antagonist examples include compounds described in WO02 / 16311 and compounds described in WO02 / 20462.
- EP 4 ⁇ Gore of the present invention - strike or using the combination agent of the EP 4 Agoyusuto and other drugs of this ⁇ the above purpose are normally administered systemically or locally, orally or parenteral form, Is administered.
- Dosage varies depending on age, weight, symptoms, therapeutic effect, administration method, treatment time, etc., but usually once per adult, once to several times a day in the range of Ol ng to l OO Omg Orally administered force, or once parenterally in the range of 0.1 ng to 10 Omg per adult per dose, or intravenously in the range of 1 to 24 hours per day Is administered continuously.
- the dose varies depending on various conditions, and therefore, a dose smaller than the above dose may be sufficient, or administration beyond the range may be necessary.
- Examples of solid preparations for internal use for oral administration include tablets, pills, capsules, powders, and condyles.
- Force pushers include hard capsules and soft force pushers.
- Tablets include sublingual tablets, intraoral adhesive tablets, and intraoral quick disintegrating tablets.
- one or more of the active substances can be used as is or as excipients (latatose, mannitol, glucose, microcrystalline cellulose, starch, etc.), binders (hydroxypropylcellulose, Mixed with Livylpyrrolidone, magnesium aluminate metasilicate), disintegrating agent (calcium glycol glycolate, etc.), lubricant (magnesium stearate, etc.), stabilizer, solubilizer (glutamic acid, aspartic acid, etc.), etc. It is formulated and used according to a conventional method.
- a coating agent sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylose cellulose phthalate, etc.
- a coating agent such as gelatin, hydroxypropylcellulose, hydroxypropylmethylose cellulose phthalate, etc.
- capsules of absorbable substances such as gelatin.
- the sublingual tablet is produced according to a known method.
- one or more active substances with excipients (latatose, mannitol, glucose, microcrystalline cellulose, colloidal silica, starch, etc.), binders (hydroxypropylcellulose, polybululpyrrolidone, magnesium aluminate metasilicate) Etc.), disintegration 3 ⁇ 4 ⁇ (starch, L-hydroxypropylsenololose, carboxymethylcellulose, croscarmellose sodium, calcium cellulose glycolate, etc.), lubricant (magnesium stearate, etc.), swelling agent (hydroxypropyl) Cellulose, Hydroxypropinoremethino Resenellose, Carbo Ponole, Forced Rubixymethinolecellulose, Polyvinylenorecol, Xanthan Gum, Gua Gugam, etc.) Swelling aid (glucose, fructose, man Thor, Xylitol, Erythri
- the intraoral patch is prepared according to a known method.
- one or more active substances with excipients (latatose, mannitol, glucose, microcrystalline cellulose, colloidal silica, starch, etc.), binders (hydroxypropylcellulose, polybululpyrrolidone, magnesium aluminate metasilicate) ), Disintegrating agents (starch, L-hydroxypropyl cellulose, carboxymethyl cellulose, croscarmellose sodium, calcium glycolate glycolate, etc.), lubricants (magnesium stearate, etc.), adhesives (hydroxypropinore Senolerose, Hydroxypropinoremethinoresenorelose, Carbopol, Force Noreboxymethinolese / Reloose, Polyvue / Rare / Reconole, Xanthan gum, Gua gum, etc.) Adhesion aid (glucose, fructose) , Mannitol, xylitol, erythritol, manoleose, treha
- a coating agent sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, etc.
- additives such as preservatives, antioxidants, colorants, sweeteners and the like that are commonly used can be added as necessary.
- the intraoral quick disintegrating tablet is prepared according to a known method.
- one or more active substances can be used as is, or a coating agent (such as ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, acrylic acid methacrylic acid copolymer) suitable for the raw powder or granulated powder.
- a coating agent such as ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, acrylic acid methacrylic acid copolymer
- Plasticizers polyethylene glycol, triethyl citrate, etc.
- excipients lactatose, mannitol, glucose, microcrystalline cell port
- binders hydroxypropyl senocellulose, polybutylpyrrolidone, magnesium metasilicate aluminate, etc.
- disintegrating agents starch, L-hydroxypropylcellulose, carboxymethylcellulose, cloth
- lubricant magnesium stearate, etc.
- dispersion aid glucose, funolectos, mannitol, xyli tonole, erythritole, manoletos, trehalose, phosphate, citrate Salt, silicate, glycine, gnoretamic acid, algene, etc.
- stabilizer solubilizer
- a coating agent sucrose, gelatin, hydroxypropinoresenorerose, hydroxypropizolemethenoresenoleose phthalate, etc.
- a coating agent sucrose, gelatin, hydroxypropinoresenorerose, hydroxypropizolemethenoresenoleose phthalate, etc.
- additives such as preservatives, antioxidants, colorants, sweeteners and the like that are commonly used can be added as necessary.
- Liquid preparations for internal use for oral administration include pharmaceutically acceptable solutions, suspensions, emulsions, syrups, elixirs and the like.
- a solution one or more active substances are dissolved, suspended or emulsified in a commonly used diluent (purified water, ethanol or a mixture thereof).
- this liquid preparation may contain a wetting agent, a suspending agent, an emulsifier, a sweetening agent, a flavoring agent, a fragrance, a preservative, a buffering agent and the like.
- External dosage forms for parenteral administration include, for example, ointments, gels, tablets, poultices, patches, ligaments, B sprays, inhalants, sprays, aerosols Includes nasal drops.
- These contain one or more active substances and are prepared by known methods or commonly used formulations.
- the ointment is produced by a known or commonly used formulation. For example, Manufactured by grinding or melting one or more active substances into a base.
- the ointment base is selected from known or commonly used ones.
- higher fatty acid or higher fatty acid ester adipic acid, myristic acid, palmitic acid, stearic acid, oleic acid, adipic acid ester, myristic acid ester, palmitic acid ester, stearic acid ester, oleic acid ester, etc.
- wax E.g.
- spermaceti ceresin, etc.
- surfactant polyoxyethylene alkynoleatenorephosphate, etc.
- higher alcohols cetanol, stearyl alcohol, cetostearyl alcohol, etc.
- silicone oil dimethylpolysiloxane
- Hydrocarbons hydrophilic petrolatum, white petrolatum, purified lanolin, liquid paraffin, etc.
- glycols ethylene glycol, jetylene glycol, propylene glycol, polyethylene glycol, macrogo Oil, castor oil, olive oil, sesame oil, turpentine oil, etc., animal oil (mink oil, egg yolk oil, squalene, squalene, etc.), water, absorption promoter, anti-rash agent, alone or in combination Are used as a mixture.
- it may contain humectants, preservatives, stabilizers, antioxidants, flavoring agents and the like.
- the gel is produced by a known or commonly used formulation. For example, it is prepared by melting one or more active substances in a base.
- the gel base is selected from known or commonly used ones. For example, lower alcohols (ethanol, isopropyl alcohol, etc.), gelling agents (carboxymethylosenololose, hydroxychetinoresenorelose, hydroxypropinoresenoreose, ethylcellulose, etc.), neutralizing agents ( Triethanolamine, diisopropanolamine, etc.), surfactant (polyethylene glycol monostearate, etc.), gums, water, absorption promoter, anti-rash agent, or a mixture of two or more. It is done.
- lower alcohols ethanol, isopropyl alcohol, etc.
- gelling agents carboxymethylosenololose, hydroxychetinoresenorelose, hydroxypropinoresenoreose, ethylcellulose, etc.
- neutralizing agents Triethanolamine, diis
- the cream is produced by a known or commonly used formulation. For example, it is prepared by melting or emulsifying one or more active substances in a base.
- the cream base is selected from known or commonly used ones. For example, higher fatty acid esters, lower alcohols, hydrocarbons, polyhydric alcohols (propylene glycol, 1,3-butylene glycol, etc.), higher alcohols (2-hexyldecanol, cetanol, etc.), emulsifiers (polyoxyethylene) Lenalkyl ethers, fatty acid esters, etc.), water, absorption accelerators, anti-rash agents, or a mixture of two or more. Further, it may contain a preservative, an antioxidant, a flavoring agent and the like.
- the poultice is produced by a known or commonly used formulation. For example, it is produced by melting one or more active substances in a base material, and spreading and applying the mixture on a support.
- the compress base is selected from known or commonly used ones. For example, thickeners (polyacrylic acid, polybutylpyrrolidone, gum arabic, starch, gelatin, methylcellulose, etc.), wetting agents (urea, glycerin, propylene glycol, etc.), fillers (kaolin, oxide oxide 0, tark, Calcium, magnesium, etc.), water, dissolution aids, tackifiers, anti-rash agents, or a mixture of two or more. In addition, it may contain preservatives, antioxidants, flavoring agents and the like.
- the patch is produced by a known or commonly used formulation. For example, one or more active '1 to raw materials are melted in a base and spread-coated on a support.
- the patch base is selected from known or commonly used ones. For example, one selected from polymer bases, fats and oils, higher fatty acids, tackifiers and anti-rash agents may be used alone or in admixture of two or more. Further, it may contain a preservative, an antioxidant, a flavoring agent and the like.
- the liniment is produced by a known or commonly used formulation.
- one or more actives can be added to water, alcohol (ethanol, poly Ethylene glycol, etc.), higher fatty acids, glycerin, soap, emulsifiers, suspending agents, etc., alone or in combination of two or more, prepared by dissolving, suspending or emulsifying. Further, it may contain a preservative, an antioxidant, a flavoring agent and the like.
- Sprays, inhalants, and sprays are commonly used diluents as well as buffers that provide isotonicity with stabilizers such as sodium bisulfite, such as sodium chloride, sodium taenate, or quenate.
- An isotonic agent such as A method for producing a spray is described in detail in, for example, US Pat. Nos. 2,868,691 and 3,095,355.
- Inhalants for parenteral administration include aerosols, inhalation powders or inhalation solutions, which are used by dissolving or suspending in water or other suitable medium at the time of use. Form may be sufficient.
- preservatives benzalkonium chloride, parabens, etc.
- coloring agents for example, preservatives (benzalkonium chloride, parabens, etc.), coloring agents, buffering agents (sodium phosphate, sodium oxalate, etc.), isotonic agents (salts) Sodium, concentrated glycerin, etc.), thickeners (such as carboxibyl polymer), absorption enhancers, etc., as necessary.
- lubricants stearic acid and its salts
- binders starch, dextrin, etc.
- excipients lactose, cellulose, etc.
- coloring agents preservatives (benzalkonium chloride, parabens) Etc.) It is prepared by appropriately selecting an absorption accelerator or the like as necessary.
- a nebulizer (atomizer or neplyzer) is usually used to administer an inhalation solution, and an inhaler for powder medicine is usually used to administer a powder for inhalation.
- injections for parenteral administration include solutions, suspensions, emulsions, and solid injections that are used by dissolving or suspending in solutions for use.
- injectables are used by dissolving, suspending or emulsifying one or more active substances in a solvent.
- the solvent include distilled water for injection, physiological saline, vegetable oil, propylene glycol, polyethylene glycol, alcohols such as ethanol, and combinations thereof.
- this injection contains a stabilizer, a dissolution aid (glutamic acid, aspartic acid, polysorbate 80 (registered trademark), etc.), a suspending agent, an emulsifier, a soothing agent, a buffering agent, a preservative, and the like. Also good. These are sterilized in the final process or manufactured by aseptic manipulation.
- aseptic solid preparations such as lyophilized products can be produced and used by dissolving them in sterilized or sterile distilled water for injection or other solvents before use.
- compositions for parenteral administration include suppositories for rectal administration and pessaries for intravaginal administration, which contain one or more active substances and are prescribed by conventional methods.
- the above-mentioned injection can be injected into the bladder.
- EP 4 agonists are useful as preventive and / or therapeutic agents for lower urinary tract diseases.
- it is useful as a preventive or therapeutic agent for cystitis and Z or urethritis.
- EP 4 ⁇ GORE - strike to be useful as a prophylactic and or therapeutic agent for lower urinary tract disease, a symptom of a lower urinary tract disease (1) urinary frequency, (2) urinary urgency, ( 3) Genital and Z or lower urinary tract pain (eg, bladder pain, urethral pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain, etc.) and Z or (4) genital pain It is also useful for improving discomfort in the lower urinary tract.
- Figure 1 shows compound 1 (4— [(2— ⁇ (2 R) — 2— [(1 E, 3 S) -4- (4 ⁇ Fu / Leo mouth Feninore)) 1 3-H It is a graph showing the effect (cyclophosphamide-induced rat cystitis model) of droxypter 1- / l] 15-oxopyrrolidine 1- 1 isle ⁇ ethyl) sulfanyl] butanoic acid).
- FIG. 2 is a graph showing the effect of Compound 1 (cyclophosphamide-induced rat cystitis model) on bladder compliance.
- FIG. 3 is a graph showing the effect of Compound 1 on micturition pressure (cyclophosphamide-induced rat cystitis model). BEST MODE FOR CARRYING OUT THE INVENTION
- Example 1 Effect in a cyclophosphamide-induced cystitis model
- mice Female Wistar rats (around 9 weeks old) were anesthetized by injecting pentobarbital sodium (4 Omgkg) into the abdominal cavity, and the lower abdomen was incised midline and the top of the bladder was incised. A catheter for measuring intravesical pressure filled with physiological saline was inserted into the bladder through the top hole. The other end of the katate ⁇ was fixed subcutaneously on the back. After infusion of O.lm L into the muscle of the rat buttocks, Vicillin S 500 (Meiji Seika) dissolved in distilled water so that the O mg titer is Zm L The following treatment was applied.
- pentobarbital sodium 4 Omgkg
- test compound was orally administered at each dose 30 minutes before cyclophosphamide treatment and 4, 20, 30 and 45 hours after cyclophosphamide treatment, respectively.
- the solvent group (hereinafter sometimes referred to as “vehicle”) was orally administered with distilled water, which is a medium for the test compound.
- cystometry was performed 48 hours after cyclophosphamide treatment.
- Rats were housed in a Ballman cage under anesthesia with jetyl ether, and a three-way stopcock was connected to the tip of a previously placed catheter for measuring intravesical pressure. One end was connected to the pressure transducer and the other end was infused. The syringe was connected to an intravesical syringe set in a pump. The intravesical pressure signal from the pressure transducer was recorded using a strain pressure amplifier recorder.
- the treatment also significantly reduced bladder compliance, which indicates the extensibility of the bladder ( Figure 2).
- EP 4 agonist 4— [(2- ⁇ (2R) -2- [(1 E, 3 S) -4- (4-fluorofeel)] 1-hydroxybutter 1-el] 1 5 1-oxopyrrolidine-1-yl ⁇ ethyl) sulfanyl] butanoic acid (hereinafter sometimes abbreviated as compound 1) was administered orally by soOiigZkg, resulting in decreased bladder capacity and decreased bladder compliance induced by cyclophosphamide.
- the improvement effect was shown (Fig. 1, Fig. 2).
- Compound 1 decreased with or without cyclophosphamide treatment (Fig. 3).
- EP 4 ⁇ GORE - strike are useful as pharmaceuticals in the following points.
- EP 4 7 Gonisu DOO is useful as a preventive Contact Yopi Z or therapeutic agent for lower urinary tract diseases.
- it is useful as a preventive and Z or therapeutic agent for cystitis and Z or urethritis.
- EP 4 agonist is useful as a preventive and Z or therapeutic agent for lower urinary tract diseases, and is a symptom of lower urinary tract diseases (1) frequent urination, (2) urgency, (3 ) Genital and Z or lower urinary tract pain (eg, bladder pain, urethral pain, vulvar pain, vaginal pain, scrotal pain, perineal pain, pelvic pain, etc.) and / or (4) genital pain It is useful for improving the discomfort of the lower urinary tract.
- EP 4 ⁇ GORE - strike are useful as agent for improving bladder capacity Contact Yopi Z or bladder compliance.
- EP 4 agonists are useful as protective and / or regeneration promoters for bladder mucosa and Z or bladder epithelial cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05770606A EP1782830A4 (en) | 2004-08-10 | 2005-08-09 | PREVENTION AND / OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING AN EP4 AGONIST |
US11/660,043 US7858610B2 (en) | 2004-08-10 | 2005-08-09 | Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist |
JP2006531778A JP4888775B2 (ja) | 2004-08-10 | 2005-08-09 | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004/232985 | 2004-08-10 | ||
JP2004232985 | 2004-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006016689A1 true WO2006016689A1 (ja) | 2006-02-16 |
Family
ID=35839443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/014875 WO2006016689A1 (ja) | 2004-08-10 | 2005-08-09 | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US7858610B2 (ja) |
EP (1) | EP1782830A4 (ja) |
JP (1) | JP4888775B2 (ja) |
WO (1) | WO2006016689A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006129788A1 (ja) * | 2005-06-03 | 2006-12-07 | Ono Pharmaceutical Co., Ltd. | 神経再生および/または保護剤 |
WO2008136519A1 (ja) * | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 |
WO2009148163A1 (ja) * | 2008-06-06 | 2009-12-10 | 小野薬品工業株式会社 | 膀胱排尿筋収縮および尿道括約筋弛緩剤 |
US7833995B2 (en) | 2003-12-05 | 2010-11-16 | Ono Pharmaceutical Co., Ltd. | Blood flow promoters for cauda equina tissues |
WO2010143661A1 (ja) * | 2009-06-10 | 2010-12-16 | 小野薬品工業株式会社 | 膀胱排尿筋収縮および尿道括約筋弛緩作用を有する化合物 |
WO2013004291A1 (en) | 2011-07-04 | 2013-01-10 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor agonists |
WO2013018837A1 (ja) | 2011-08-02 | 2013-02-07 | 小野薬品工業株式会社 | 左室拡張機能改善剤 |
JPWO2014034902A1 (ja) * | 2012-08-31 | 2016-08-08 | 小野薬品工業株式会社 | アミン塩とその結晶 |
US10988468B2 (en) | 2017-12-25 | 2021-04-27 | Asahi Kasei Pharma Corporation | Nitrogen-containing 6-membered cyclic compound |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013109202A2 (en) * | 2012-01-18 | 2013-07-25 | Mahmut Bilgic | Pharmaceutical compounds comprising cefetamet |
AU2013292357C1 (en) | 2012-07-19 | 2017-05-25 | Cayman Chemical Company, Inc. | Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated disease and conditions |
WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
BR112015023080A2 (pt) | 2013-03-15 | 2017-07-18 | Cayman Chemical Co Inc | composto, composição farmacêutica, e, método para tratamento de doenças |
AU2014290512A1 (en) | 2013-07-19 | 2015-11-12 | Cayman Chemical Company, Inc. | Methods, systems, and compositions for promoting bone growth |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000003980A1 (fr) * | 1998-07-15 | 2000-01-27 | Ono Pharmaceutical Co., Ltd. | DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF |
WO2002016311A1 (fr) * | 2000-08-22 | 2002-02-28 | Ono Pharmaceutical Co., Ltd. | Derives d'acide carboxylique, procede de production de ceux-ci et medicaments contenant ceux-ci comme principe actif |
WO2003009872A1 (en) * | 2001-07-23 | 2003-02-06 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
WO2003016254A1 (fr) * | 2001-08-09 | 2003-02-27 | Ono Pharmaceutical Co., Ltd. | Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif |
WO2003043655A1 (fr) * | 2001-11-19 | 2003-05-30 | Ono Pharmaceutical Co., Ltd. | Remedes pour la frequence urinaire |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002015902A1 (en) * | 2000-08-23 | 2002-02-28 | Merck & Co., Inc. | Method of treating or preventing urinary incontinence using prostanoid ep1 receptor antagonists |
US6986005B2 (en) * | 2001-12-31 | 2006-01-10 | Hewlett-Packard Development Company, L.P. | Low latency lock for multiprocessor computer system |
KR100604865B1 (ko) * | 2004-06-08 | 2006-07-26 | 삼성전자주식회사 | 신호 대 잡음비가 향상된 aps 셀 |
-
2005
- 2005-08-09 EP EP05770606A patent/EP1782830A4/en not_active Withdrawn
- 2005-08-09 JP JP2006531778A patent/JP4888775B2/ja not_active Expired - Fee Related
- 2005-08-09 US US11/660,043 patent/US7858610B2/en not_active Expired - Fee Related
- 2005-08-09 WO PCT/JP2005/014875 patent/WO2006016689A1/ja active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000003980A1 (fr) * | 1998-07-15 | 2000-01-27 | Ono Pharmaceutical Co., Ltd. | DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF |
WO2002016311A1 (fr) * | 2000-08-22 | 2002-02-28 | Ono Pharmaceutical Co., Ltd. | Derives d'acide carboxylique, procede de production de ceux-ci et medicaments contenant ceux-ci comme principe actif |
WO2003009872A1 (en) * | 2001-07-23 | 2003-02-06 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
WO2003016254A1 (fr) * | 2001-08-09 | 2003-02-27 | Ono Pharmaceutical Co., Ltd. | Composes derives d'acide carboxylique et medicaments comprenant ces composes comme principe actif |
WO2003043655A1 (fr) * | 2001-11-19 | 2003-05-30 | Ono Pharmaceutical Co., Ltd. | Remedes pour la frequence urinaire |
Non-Patent Citations (1)
Title |
---|
See also references of EP1782830A4 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7833995B2 (en) | 2003-12-05 | 2010-11-16 | Ono Pharmaceutical Co., Ltd. | Blood flow promoters for cauda equina tissues |
US8501793B2 (en) | 2003-12-05 | 2013-08-06 | Ono Pharmaceutical Co., Ltd. | Blood flow promoters for cauda equina tissues |
US8404858B2 (en) | 2005-06-03 | 2013-03-26 | Ono Pharmaceutical Co., Ltd. | Agent for regeneration and/or protection of nerves |
US7863263B2 (en) | 2005-06-03 | 2011-01-04 | Ono Pharmaceutical Co., Ltd. | Agent for regeneration and/or protection of nerves |
WO2006129788A1 (ja) * | 2005-06-03 | 2006-12-07 | Ono Pharmaceutical Co., Ltd. | 神経再生および/または保護剤 |
WO2008136519A1 (ja) * | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Ep4アゴニストを含有してなる細胞傷害性t細胞の活性化剤 |
US8507545B2 (en) | 2007-05-08 | 2013-08-13 | National University Corporation, Hamamatsu University School Of Medicine | Cytotoxic T cell activator comprising EP4 agonist |
WO2009148163A1 (ja) * | 2008-06-06 | 2009-12-10 | 小野薬品工業株式会社 | 膀胱排尿筋収縮および尿道括約筋弛緩剤 |
JP5630264B2 (ja) * | 2008-06-06 | 2014-11-26 | 小野薬品工業株式会社 | 膀胱排尿筋収縮および尿道括約筋弛緩剤 |
KR20120026088A (ko) * | 2009-06-10 | 2012-03-16 | 오노 야꾸힝 고교 가부시키가이샤 | 방광 배뇨근 수축 및 요도 괄약근 이완 작용을 갖는 화합물 |
US8410281B2 (en) | 2009-06-10 | 2013-04-02 | Ono Pharmaceutical Co., Ltd. | Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity |
KR101633149B1 (ko) | 2009-06-10 | 2016-06-23 | 오노 야꾸힝 고교 가부시키가이샤 | 방광 배뇨근 수축 및 요도 괄약근 이완 작용을 갖는 화합물 |
US9150528B2 (en) | 2009-06-10 | 2015-10-06 | Ono Pharmaceutical Co., Ltd. | Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity |
US8716490B2 (en) | 2009-06-10 | 2014-05-06 | Ono Pharmaceutical Co., Ltd. | Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity |
WO2010143661A1 (ja) * | 2009-06-10 | 2010-12-16 | 小野薬品工業株式会社 | 膀胱排尿筋収縮および尿道括約筋弛緩作用を有する化合物 |
WO2013004291A1 (en) | 2011-07-04 | 2013-01-10 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor agonists |
JPWO2013018837A1 (ja) * | 2011-08-02 | 2015-03-05 | 小野薬品工業株式会社 | 左室拡張機能改善剤 |
CN103717219A (zh) * | 2011-08-02 | 2014-04-09 | 小野药品工业株式会社 | 左心室舒张功能改善剂 |
WO2013018837A1 (ja) | 2011-08-02 | 2013-02-07 | 小野薬品工業株式会社 | 左室拡張機能改善剤 |
CN103717219B (zh) * | 2011-08-02 | 2017-02-15 | 小野药品工业株式会社 | 左心室舒张功能改善剂 |
US9682065B2 (en) | 2011-08-02 | 2017-06-20 | Ono Pharmaceutical Co., Ltd. | Left ventricular diastolic function improving agent |
JPWO2014034902A1 (ja) * | 2012-08-31 | 2016-08-08 | 小野薬品工業株式会社 | アミン塩とその結晶 |
US9643940B2 (en) | 2012-08-31 | 2017-05-09 | Ono Pharmaceutical Co., Ltd. | Amine salt and crystals thereof |
US10988468B2 (en) | 2017-12-25 | 2021-04-27 | Asahi Kasei Pharma Corporation | Nitrogen-containing 6-membered cyclic compound |
US11667630B2 (en) | 2017-12-25 | 2023-06-06 | Asahi Kasei Pharma Corporation | Nitrogen-containing 6-membered cyclic compound |
Also Published As
Publication number | Publication date |
---|---|
JP4888775B2 (ja) | 2012-02-29 |
JPWO2006016689A1 (ja) | 2008-05-01 |
US7858610B2 (en) | 2010-12-28 |
EP1782830A1 (en) | 2007-05-09 |
US20080021021A1 (en) | 2008-01-24 |
EP1782830A4 (en) | 2009-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115867533B (zh) | 色胺前药 | |
AU2004273610B2 (en) | Prevention and treatment of inflammation-induced and/or immune-mediated bone loss | |
JP5387997B2 (ja) | 血管の収縮または拡張による疾患治療剤 | |
WO2006016689A1 (ja) | Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤 | |
WO2019109937A1 (zh) | Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途 | |
WO2006016695A1 (ja) | Ep4アゴニストを含有してなる高カリウム血症の予防および/または治療剤 | |
TWI404529B (zh) | 神經再生及/或保護劑 | |
JP6569661B2 (ja) | 選択的ep2アゴニスト活性を有する化合物 | |
TWI336254B (en) | Pharmaceutical composition for treating abdominal discomfort | |
JP2007023028A (ja) | 内耳疾患治療剤 | |
WO2006025324A1 (ja) | トロパン化合物およびそれらを有効成分として含有する医薬組成物 | |
JP4788999B2 (ja) | 分枝鎖カルボン酸化合物およびその用途 | |
WO2004089411A1 (ja) | 脊柱管狭窄症治療剤 | |
US20090286862A1 (en) | Therapeutic agent for psychoneurotic disease | |
ES2837399T3 (es) | Derivados de ácido 2-(octahidrociclopenta(b)piran-2-il)1,3-tiazol-4-carboxílico y compuestos relacionados como agonistas de EP2 con actividad reductora de la presión intraocular | |
JP2006321737A (ja) | Ep4アゴニストを含有する神経変性疾患の予防、治療および/または進展抑制剤 | |
JP5630264B2 (ja) | 膀胱排尿筋収縮および尿道括約筋弛緩剤 | |
JP2006021998A (ja) | Ep2アゴニストを有効成分とする月経困難症治療剤 | |
JP2006016318A (ja) | 2−プロピルオクタン酸の脳移行性向上プロドラッグおよびその用途 | |
JP2006016319A (ja) | プロドラッグ | |
WO2006090850A1 (ja) | ベンズアミド化合物 | |
JP2017043606A (ja) | 医薬用途 | |
JP2005097196A (ja) | N型カルシウムチャンネル阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006531778 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11660043 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005770606 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005770606 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11660043 Country of ref document: US |